

In vivo aphrodisiac efficacy of aqueous and hydroalcoholic extracts of the leaf and root bark of *Citropsis articulata* in male Wistar rats

Anyase Ronald Amaza

ra.anyase@muni.ac.ug

Mbarara University of Science and Technology

Treasure Angie Amutuhaire

Mbarara University of Science and Technology

Jonans Tusiimire

Mbarara University of Science and Technology

Vivian Sharon Amito

Mbarara University of Science and Technology

Clement Olusoji Ajayi

Mbarara University of Science and Technology

Jimmy Ronald Angupale

Mbarara University of Science and Technology

Abdelgadir Alamin Abdelgadir

University of Gezira

Anywar Godwin

Makerere University

Patrick Engeu Ogwang

Mbarara University of Science and Technology

Research Article

Keywords: *Citropsis articulata*, aphrodisiac, testosterone, male sexual behaviour, mount frequency

Posted Date: August 27th, 2024

DOI: <https://doi.org/10.21203/rs.3.rs-4784543/v1>

License: © ⓘ This work is licensed under a Creative Commons Attribution 4.0 International License.

[Read Full License](#)

Additional Declarations: No competing interests reported.

1 ***In vivo* aphrodisiac efficacy of aqueous and hydroalcoholic extracts of the leaf and root**
2 **bark of *Citropsis articulata* in male Wistar rats**

3 Anyase Ronald Amaza ^{1,2,3*}, Treasure Angie Amutuhaire ¹, Jonans Tusiimire ¹,
4 Vivian Sharon Amito ^{1,2}, Clement Olusoji Ajayi ^{1,2}, Jimmy Ronald Angupale ^{2,4},
5 Abdelgadir Alamin Abdelgadir ^{2,5,6}, Anywar Godwin ⁷, Patrick Engeu Ogwang ^{1,2}

6 ¹ Department of Pharmacy, Faculty of Medicine, Mbarara University of Science and
7 Technology, P. O. Box 1410, Mbarara, Uganda

8 ² Pharm-Biotechnology and Traditional Medicine Centre, Mbarara University of Science and
9 Technology, P. O. Box 1410, Mbarara, Uganda

10 ³ Department of Nursing and Midwifery, Faculty of Health Sciences, Muni University, P. O.
11 Box 725, Arua, Uganda

12 ⁴ Department of Pharmaceutical Sciences, Faculty of Medicine, Mbarara University of
13 Science and Technology, P. O. Box 1410, Mbarara, Uganda

14 ⁵ Department of Pharmacognosy, Faculty of Pharmacy, University of Gezira, P.O. Box 20,
15 Wad Medani, Gezira, Sudan

16 ⁶ Department of Medical Sciences and Preparation Year, Northern College of Nursing, Arar,
17 73312, Saudi Arabia

18 ⁷ Department of Plant Sciences, Microbiology and Biotechnology, College of Natural
19 Sciences, Makerere University, P.O. Box 7062, Kampala, Uganda

20 ***Corresponding Author:**

21 aronaldamaza@std.must.ac.ug/ra.anyase@muni.ac.ug/+256752033629

- 22 **Other Authors:** Treasure Angie Amutuhaire; atreasureangie@std.must.ac.ug/Jonans
- 23 Tusiimire; jonanstusiimire@must.ac.ug/Vivian Sharon Amito;
- 24 aviviansharon@std.must.ac.ug/Clement Olusoji Ajayi; aolusoji@std.must.ac.ug/Jimmy
- 25 Ronald Angupale; jangupale@must.ac.ug/Abdelgadir Alamin Abdelgadir;
- 26 gadora313@uofg.edu.sd, gadora-313@hotmail.com, abdelgadir24@gmail.com/Anywar
- 27 Godwin; godwin.anywar@mak.ac.ug/godwinanywar@gmail.com/Patrick Engeu Ogwang;
- 28 pogwang@must.ac.ug

29 **Abstract**

30 **Background:** The African cherry orange tree *Citropsis articulata* Swingle & Kellerman
31 (family Rutaceae) is traditionally used to manage erectile dysfunction. This study aimed to
32 determine the aphrodisiac activity of *C. articulata* leaves and root bark in male Wistar rats.

33 **Methods:** Aqueous and hydroalcoholic extracts of leaves and root bark were prepared via
34 decoction and soxhlation, respectively. Extracts were administered to the animals at three dose
35 levels, i.e., 100, 500 and 1000 mg/kg. Six male animals (aged 8–12 weeks, weighing 140–200
36 g) were used in each of the groups. Three animals per group (group B), unlike those
37 immediately sacrificed at the end of 28 days (group A), were left for an extra 14 days without
38 dosing to look out for delayed or sustained efficacy signs. Male sexual behavior, including
39 attraction towards the female, penile erection, mount frequency, and mount latency, was
40 monitored on days 0, 3, 7, 14, 21, 28, 35 and 42. At the end of both 28 days and the extra 14
41 days, the animals were humanely sacrificed via anesthesia with halothane, and their blood was
42 collected for testosterone level analysis, while the sexual organs harvested were assessed
43 grossly and histologically.

44 **Results:** *Citropsis articulata* root bark and leaves increased the attraction towards the female,
45 penile erection, and mount frequency while lowering the mount latency. The plant extracts also
46 increased testosterone levels after 28 days of daily extract administration but greatly lowered
47 the testosterone levels in the animals that were left for an extra 14 days without dosing. Even
48 histologically, there was the first evidence of very active spermatogenesis, which disappeared
49 when the administration of the extract ceased. The administration of *C. articulata* leaf
50 decoction at a dose of 500 mg/kg significantly increased the testosterone level (14.50 ± 2.53
51 ng/ml) compared with that of the positive control (4.00 ± 2.70 ng/ml), with a p-value of 0.021
52 (confidence interval: -19.45 to -1.533).

53 **Conclusion:** This study revealed that both the root bark and leaf of *Citropsis articulata* have
54 aphrodisiac efficacy in male Wistar rats *in vitro*.

55 **Keywords:** *Citropsis articulata*, aphrodisiac, testosterone, male sexual behaviour, mount
56 frequency

57 **1. Background**

58 The management of erectile dysfunction may involve lifestyle modifications, nonsurgical and
59 surgical procedures (Yafi et al., 2016). Conventionally, nonsurgical methods involve the use
60 of mainly phosphodiesterase 5 inhibitor drugs but also vacuum erection devices, intraurethral
61 suppositories, and intracavernosal injections. The use of phosphodiesterase 5 inhibitor drugs
62 has various adverse effects, including headache, heartburn, facial flushing, nasal congestion,
63 visual disturbances, tinnitus, hypotension and priapism (1). Owing to some of the adverse
64 effects of these therapies, there has been a shift toward natural plant-based remedies.

65 The aphrodisiac potential of medicinal plants has been traditionally known since time
66 immemorial. It refers to the ability to enhance male sexual function by increasing desire,
67 arousal, and performance. Singh *et al.* (2012) listed approximately 198 medicinal plants with
68 aphrodisiac potential. Plants with aphrodisiac potential are traditionally used to treat erectile
69 dysfunction. Erectile dysfunction is the recurring failure to obtain and retain an erection
70 sufficient for sexual intercourse in men. The etiology of erectile dysfunction is multicausal.
71 This could be due to psychogenic, neurogenic, vasculogenic, iatrogenic, and/or endocrine
72 causes (3).

73 Medicinal plants and herbal products are rapidly increasing alternatives to conventional
74 treatments for erectile dysfunction. Some of the known aphrodisiac medicinal plants include
75 *Citropsis articulata*, *Kigelia africana*, *Panax ginseng*, *Rumex usambarensis*, *Mondia whitei*,
76 *Acanthus pubescens*, *Lactuca inermis*, *Kalanchoë densiflora*, *Acalypha villicaulis*, *Rhus*
77 *vulgaris*, *Balanites aegyptiaca*, *Carica papaya*, *Tragia benthamii*, *Rumex abyssinicus*, *Coffea*
78 *eugenioides*, *Capsicum frutescens*, *Solanum incanum*, *Zingiber officinale*, *Cola acuminata*,
79 *Aframomum melegueta*, and *Garcinia kola* (4–6).

80 *Citropsis articulata* is one of the most treasured medicinal plants in southwestern Uganda and
81 is often referred to as a natural “Viagra” (7). It is called “Omuboro” in Runyankore-Rukiga
82 language and “katimboro” in Rutooro (4,8). Traditionally, the plant is wholly uprooted, and
83 the tap root is debarked. This bark can be chewed fresh or shredded, dried and pounded to
84 make a powder (9). The powder can then be infused in hot water or boiled, and the extract
85 can be taken once a day for up to three days to increase sexual performance. The leaves of
86 this plant are also gaining popularity as an alternative to the root bark for the same purpose
87 (7,10). This plant is a vulnerable species according to the Red List of Threatened Species of
88 Uganda (11). It is becoming depleted at an alarming rate from the tropical rainforests in
89 which it favorably grows. This has been attributed to unsustainable methods of harvesting
90 and overexploitation of the plant due to its high demand (12).

91 Whereas Gakunga et al. (2014) and Vudriko et al. (2014) studied the leaf of *C. articulata*,
92 few studies have investigated the aphrodisiac properties of the more traditionally used part,
93 i.e., the root bark. In this study, we simultaneously determined the aphrodisiac activity of
94 both the root bark and leaves of *C. articulata* in Wistar albino rats. This study not only
95 validated the traditional use of the root bark but also provided insight for comparison with
96 leaves as a viable alternative.

97 **Methods**

98 **Plant collection and processing**

99 The plant materials were obtained from Kibale Conservation Area (Latitude – N 0° 26’8”
100 Longitude – E 30° 23’8”, Altitude 1252.7 m) in southwestern Uganda in July and August 2021
101 following the World Health Organization guidelines on good agricultural and collection
102 practices for medicinal plants (13). Prior approval (reference number: COD/96/05) was
103 obtained from the Uganda Wildlife Authority before plant collection. An herbarium specimen
104 (ARA 004) was prepared and submitted to the Makerere University Herbarium, Department of
105 Botany, identified by Mr. Protase K. Rwaburindore and given the accession number 50965.
106 The plant name was checked at <https://wfo-plantlist.org/plant-list> with the identification code
107 wfo-0000607733.

108 The roots were washed and debarked, and the leaves were directly rinsed with clean running
109 water to remove any debris. The plant materials were air dried for between 7 to 11 days. The
110 dried plant materials were then ground using an electric grinder and sieved to a moderately
111 coarse powder.

112 **Extraction**

113 The plant materials were extracted using two standard methods: decoction and soxhlation. For
114 decoction, approximately 500 g of herbal powder was boiled in 4 L of distilled water for 60
115 minutes. For soxhlation, 500 g were placed in a Soxhlet thimble and percolated with 2.5 L of
116 70% ethanol. The liquid contents were filtered through cotton wool, and the volume was
117 reduced using a rotary evaporator (IKA® RV 10 digital, Germany). Finally, the viscous
118 concentrate was lyophilized to obtain dry extracts. The percentage yield was estimated to be
119 33.47%, 27.26%, 19.27% and 21.58% for the root bark decoction, root bark Soxhlet, leaf

120 decoction and leaf Soxhlet extracts, respectively. All dry extracts were refrigerated between 2
121 and 6 °C until use.

122 **Preliminary phytochemical screening**

123 Following standard methods (14), all extracts were screened for the presence of alkaloids,
124 saponins, L-arginine, flavonoids, reducing sugars, coumarins, glycosides, and phytosterols.
125 These phytochemicals are known to contribute to the aphrodisiac potential of plants (10,15).
126 All the tests were performed in triplicate to ensure repeatability. One gram of each extract
127 was first dissolved in 50 ml of distilled water, shaken vigorously and filtered through filter
128 paper. The resulting filtrate was used for phytochemical screening, unless otherwise stated in
129 the test procedure (14). Crude and pure standard reference materials were employed as
130 positive controls (WHO, 2011).

131 **Selection and preparation of animals**

132 Male Wistar albino rats (8–12 weeks old, weighing 140–200 g) were selected for the study.
133 Natural lighting at approximately 12-hour intervals was considered sufficient to provide 12
134 hours of light and darkness each. The animals were housed in groups of 6 animals in clean
135 plastic cages and allowed an unlimited supply of drinking water and feeds. The animals were
136 allowed to acclimatize to laboratory conditions for 10 days before being used in the study.
137 Only healthy animals (with no signs of morbidity) were selected for the study. Fifteen groups
138 with 6 animals each were used for the 4 extracts (3 dose levels per extract, i.e., 1000, 500 and
139 100 mg/kg), 2 negative controls (distilled water alone and then distilled
140 water/dimethylsulfoxide containing 0.1% gum arabic) and 1 positive control. This study was
141 conducted in accordance with the Guide for the Care and Use of Laboratory Animals (16).
142 Ethical approval (reference number: MUREC 1/7) was obtained prior to experimentation.

143 **Preparation and administration of extract and control doses**

144 The decoction extracts were dissolved in distilled water to achieve a stock solution of
145 approximately 100 mg/ml. The Soxhlet extracts were dissolved in dimethylsulfoxide and
146 distilled water (1:9 ratio containing 0.1% gum arabic) to achieve a concentration of 50
147 mg/ml. Two negative control groups, distilled water and distilled water/dimethylsulfoxide
148 containing 0.1% gum arabic, were used. A positive control, i.e., sildenafil citrate at a dose of
149 5 mg/kg (Viagra®, Pfizer Pharmaceuticals Ltd., Cairo, Egypt), was also used.

150 Food but not water was withheld overnight for each animal prior to dosing. The fasted body
151 weight of each animal was determined. The actual dose in ml was calculated according to the
152 following formula: volume administered in ml = (dose in mg/kg × body weight in kg) ÷
153 concentration of extract in mg/ml. The test substance was administered slowly via gastric
154 gavage using an intubation cannula (10).

155 **Induction of estrus in female animals**

156 To render the female rats receptive to the males, they were given a suspension of estradiol
157 valerate (Progynova®, Delpharm, Bayer AG, Berlin, Germany) at a dose of 0.4 mg/kg 48
158 hours before the experiment. Progesterone (Gestone™, Ferring Pharmaceutical PVT, Ltd.,
159 Bhiwandi, India) was subsequently injected subcutaneously at a dose of 5 mg/kg
160 approximately 4–6 hours before the experiment. Only receptive females were considered for
161 the study after they were exposed to male animals other than those used for the actual study.

162 **Mating behavior – noncontact and contact studies**

163 Following the administration of the doses of the extracts or control substances, the male
164 animals were placed in one half of a transparent glass observation chamber measuring about
165 24 by 12 by 12 (length by width by height) inches. The chamber had a transparent glass
166 separation with at least one perforated hole, which allowed the transfer of auditory, visual and
167 pheromonal cues between the two animals. A receptive female animal was placed in the other

168 half of the chamber 1 hour after drug administration to the male and acclimatized to the other
169 half of the chamber. This model is referred to as the noncontact model (15,17), in which the
170 time spent by the male rat near the perforation in a 30-minute period was recorded as the
171 *attraction towards the female*. In addition, the number of times the male animal bent to lick
172 its erect penis was also recorded as *penile erection* (15).

173 After 30 minutes, the female rat was introduced into the chamber half with the male rat for
174 another 30 minutes. This was referred to as the contact model (15). The time taken by the
175 male for its first mount and the number of mounts in this period were recorded as the *mount*
176 *latency* and *mount frequency*, respectively.

177 **Gross and histological investigation**

178 For each animal, the noncontact and contact models were studied on days 0, 3, 7, 14, 21 and
179 28. At the end of 28 days, 3 animals per group were humanely sacrificed, and their sex organs
180 (penis, seminal vesicles, testes, epididymis and prostate glands) were harvested for gross and
181 histological investigation. The remaining 3 animals per group were further studied on days 35
182 and 42. This was done to assess the delayed or sustained aphrodisiac effects of the extracts
183 (18).

184 The weights of the animals were recorded weekly. The relative weights of the organs
185 (particularly the penis and testes) were also noted. During organ harvesting, the penile length
186 was also determined by measuring from the tip to the inner base of the penis. Furthermore,
187 histological investigations of the penis, seminal vesicles, testes, epididymis and prostate
188 gland were performed.

189 **Testosterone analysis**

190 At the end of day 28 and day 42, the animals were anesthetized by administration of
191 halothane followed by cardiac puncture to obtain blood for testosterone analysis. Serum

192 testosterone levels were determined via a dry-type immunofluorescence quantitative analyzer
193 (Fluorecare™, Model MF-T1000, Shenzhen Microprofit Biotech Co. Ltd., Nanshan, China),
194 which is a faster technique that employs immunochromatographic assays and fluorescence
195 detection (19).

196 **Statistical analysis**

197 The quantitative data are expressed as the means \pm SEMs ($n \geq 3$), following descriptive
198 analysis using GraphPad Prism Version 8.0.2.263. This was followed by further comparison
199 with the negative control and positive control using ordinary one-way analysis of variance.
200 Then, the *post hoc* Tukey's multiple comparisons test with a level of significance of 0.05 was
201 performed to obtain the familywise adjusted p-values and 95% confidence intervals.

202 **Results**

203 **Preliminary phytochemical screening**

204 All the phytochemical groups (alkaloids, saponins, flavonoids, reducing sugars, coumarins,
 205 glycosides, and phytosterols) and L-arginine were present in at least one of the extracts
 206 (Table 1).

207 **Table 1** Phytochemical composition of the plant extracts

| No | Test | Inference | CABD | CABS | CALD | CALS |
|----|------------------------|--------------------------|------------------|---------------|-------------|---------------------|
| 1. | Reducing sugars | +++ | + | ++ | ++ | +++ |
| | <i>Glucose</i> | <i>Reddish-brown ppt</i> | Green ppt | Orange ppt | Brown ppt | Red ppt |
| 2. | Alkaloids | +++ | +/- | +++ | - | - |
| | <i>Quinine HCL</i> | <i>Orange ppt</i> | Bluish black ppt | Orange ppt | None | None |
| 3. | Coumarin | +++ | +++ | +++ | +++ | +++ |
| | <i>Warfarin</i> | <i>Yellow</i> | Yellow | Yellow | Yellow | Yellow |
| 4. | Glycosides | +++ | +++ | +++ | +++ | +++ |
| | <i>Digoxin</i> | <i>Deep blue</i> | Deep blue | Deep blue | Deep blue | Deep blue |
| 5. | Flavonoids | +++ | +++ | +++ | + | +++ |
| | <i>Quercetin</i> | <i>Yellow ppt</i> | Yellow ppt | Yellow ppt | Cream ppt | Yellowish green ppt |
| 6. | Phytosterols | +++ | +++ | +++ | ++ | ++ |
| | <i>Beta-sitosterol</i> | <i>Golden yellow</i> | Golden yellow | Golden yellow | Deep green | Deep green |
| 7. | Saponins | +++ | + | +++ | ++ | +++ |
| | <i>Crude saponin</i> | <i>10.0 mm foam</i> | 0.5 mm foam | 11.0 mm foam | 1.0 mm foam | 7.0 mm foam |
| 8. | L-Arginine | +++ | ++ | ++ | +++ | ++ |
| | <i>L-arginine</i> | <i>Deep red</i> | Red | Red | Dark red | Red |

208 Expts: CABD – *Citropsis articulata* root bark decoction, CABS – *Citropsis articulata* root bark Soxhlet, CALD – *Citropsis articulata* leaf decoction, CALS –
 209 *Citropsis articulata* leaf Soxhlet, Relative presence/absence: +++ (high), ++ (medium), + (low), - (absent), +/- (undefined). Observations were recorded as changes in
 210 the color of the solution or the formation of colored precipitates (ppt). Reference materials (italicized) are placed below the name of the test (in bold), and their
 211 observations are recorded and noted as the inference. “None” meant that no significant observable change was noted.

212 **Mating behavior**

213 **Attraction towards the female (AF)**

214 The highest AF (833.50±98.00 s) recorded during the observation period was for *C.*
 215 *articulata* leaf decoction at a dose of 100 mg/kg on day 14. On day 7, *C. articulata* root bark
 216 Soxhlet extract at a dose of 500 mg/kg produced a statistically significant increased AF of
 217 602.00±79.92 s (p = 0.012: confidence interval (CI) = -604.3 to -66.72 when compared to the
 218 positive control. Similarly, on the same day, *C. articulata* leaf decoction extract at a dose of
 219 500 mg/kg produced a statistically significant increase in AF of 630.7±151.10 s (p = 0.016:
 220 CI = -865.7 to -67.27) compared with that of the negative control. On varying days of extract

221 administration and different dose levels, there was barely any trend association as AF
222 increased or decreased from one day to another or from one dose level to another, as depicted
223 in Table 2. However, there was a general increase in AF with increasing time, i.e., from day 0
224 to day 14, which had the highest AF values for most extracts. There was a slight decrease in
225 AF from days 14 to 28. On the nondosing days, day 42 generally had greater AFs than did
226 day 35 for all extracts except for the animals in the group that previously received the *C.*
227 *articulata* root bark Soxhlet extract at a dose of 500 mg/kg.

228 **Penile Erections**

229 On day 0, *C. articulata* root bark decoction extract at a dose of 100 mg/kg resulted in the
230 greatest number of penile erections (3.33 ± 0.99), which was significantly greater than that of
231 the negative control ($p = 0.035$: CI = -5.841 to -0.159). On day 7, *C. articulata* root bark
232 Soxhlet extract at a dose of 1000 mg/kg resulted in more penile erections (1.00 ± 0.00) than
233 did the positive control – sildenafil citrate at a dose of 5 mg/kg. This value was significantly
234 higher ($p = 0.022$: CI = -1.873 to -0.127). *Citropsis articulata* leaf decoction at doses of 500
235 and 1000 mg/kg on day 21 caused significantly more penile erections than both the negative
236 and positive controls did (Table 3). In general, for all the extracts, the number of penile
237 erections decreased from day 0 to day 7, increased from day 14 and peaked on day 21.

238 **Mount Latency**

239 During the first 28 days of extract administration, with the exception of the mount latency
240 (2.83 ± 0.60 s) elicited by the positive control on day 21, the lowest mount latency (5.50 ± 0.50
241 s) was elicited by the *C. articulata* root bark Soxhlet extract (500 mg/kg). Following dosing
242 cessation and monitoring for an additional 14 days, the lowest mount latencies (1.00 ± 1.00
243 and 3.67 ± 3.67 s) were elicited by *C. articulata* leaf Soxhlet extract at doses of 100 and 500
244 mg/kg, respectively. Although no statistically significant differences were obtained following
245 the conservative familywise analysis, it is evident that the different extracts decreased the
246 mount latency on different days examined at different dose levels (Table 4).

247 **Mount frequency**

248 On day 0, the highest mount frequency recorded was 32.83 ± 11.09 in the group treated with
249 *C. articulata* root bark decoction extract at a dose of 100 mg/kg. Additionally, on the same
250 day, *C. articulata* leaf decoction extract at a dose of 100 mg/kg elicited a statistically
251 significant number of mounts, i.e., 28.67 ± 3.67 ($p = 0.008$: CI = -32.36 to -3.969), when a

252 familywise comparison (3 dose levels and the positive and negative control) was performed
253 in relation to the negative control.

254 In general, the number of mounts decreased with increasing dose on most days for all the
255 extracts except on day 28, when the number of mounts increased with increasing dose.

256 Soxhlet extracts evoked fewer mounts than did the decoctions. On day 21, *C. articulata* leaf
257 Soxhlet extracts at all three dose levels evoked statistically significant but lower mounts than
258 the positive control. In general, day 3, followed by days 35 and 28, had the lowest number of
259 mounts for all the extracts. The highest recorded number of mounts (63.00 ± 0.00) for the
260 entire study was recorded on day 42 (2 weeks after cessation of extract dosing). *Citropsis*
261 *articulata* leaf decoction extract at a dose of 1000 mg/kg elicited a statistically significant
262 number of mounts, i.e., 42.00 ± 8.15 ($p = 0.010$: CI = -60.42 to -8.243 and $p = 0.022$: CI = -
263 56.42 to -4.243), when a familywise comparison (3 dose levels and the positive and negative
264 control) was performed in relation to the negative control and positive control, respectively.

265 Table 5 shows the details of the mount frequency for the extracts across all dose levels on
266 observation days 0, 3, 7, 14, 21, 28, 35 and 42.

Table 2 Attraction towards the female when different doses of the extracts were administered over 42 days

| No | Group | Day 0 | Day 3 | Day 7 | Day 14 | Day 21 | Day 28 | Day 35 | Day 42 |
|-----|-------|--|---|---|--|--|--|---|--|
| 1. | NC-DW | 417.8±70.04 | 224.30±106.40 | 164.20±73.16 | 617.80±156.90 | 296.50±68.50 | 503.50±94.02 | 305.30±28.88 | 516.00±100.10 |
| 2. | NC-DS | 483.80±124.20 | 220.70±48.29 | 601.50±119.50 | 519.80±74.98 | 246.30±48.59 | 242.50±59.73 | 222.70±36.10 | 403.30±121.70 |
| 3. | PC-SC | 297.20 ± 88.87 | 256.70±145.70 | 266.50±40.29 | 788.70±143.00 | 567.80±37.62 | 628.50±60.05 | 418.30±43.18 | 671.70±260.70 |
| 4. | CABD | 377.00±63.19 | 250.50±78.46 | 117.20±31.18 | 635.50±54.59 | 230.50±16.04* | 348.80±61.99 | 214.30±91.79 | 478.00±18.00 |
| | 100 | 0.997 (-348.8 to 430.4) 0.974 (-469.4 to 309.8) | 0.999 (-504.6 to 452.3) >0.99 (-472.3 to 484.6) | 0.987 (-230.4 to 324.3) 0.520 (-128.0 to 426.6) | >0.999 (-508.4 to 473.0) 0.868 (-314.7 to 621.1) | 0.732 (-94.70 to 226.7) <0.001 (223.7 to 451.0) | 0.574 (-148.7 to 458.0) 0.081 (-23.66 to 583.0) | 0.710 (-143.5 to 325.5) 0.097 (-30.54 to 438.5) | 0.999 (-819.3 to 895.3) 0.92 (-663.7 to 1051) |
| 5. | CABD | 411.20±138.40 | 216.20±62.69 | 124.20±36.93 | 522.00±52.55 | 196.80±20.65* | 363.50±55.71 | 258.70±31.67 | 319.00±0.00 |
| | 500 | >0.999 (-382.9 to 396.3) 0.999 (-369.5 to 275.6) | >0.99 (-419.8 to 436.1) 0.999 (-387.5 to 468.5) | 0.991 (-224.4 to 304.4) 0.520 (-122.1 to 406.7) | 0.978 (-394.9 to 586.5) 0.465 (-201.2 to 734.6) | 0.424 (-70.70 to 270.2) <0.001 (244.0 to 498.1) | 0.660 (-163.3 to 443.3) 0.108 (-38.32 to 568.3) | 0.962 (-187.9 to 281.2) 0.241 (-74.87 to 394.2) | 0.961 (-887.4 to 1281) 0.771 (-731.8 to 1437) |
| 6. | CABD | 271.30±89.71 | 356.30±96.31 | 372.20±101.70 | 639.00±134.00 | 260.00±23.60* | 401.70±85.30 | 254.00±23.86 | 639.00±47.72 |
| | 1000 | 0.803 (-243.1 to 536.1) 0.999 (-363.8 to 415.4) | 0.890 (-560.0 to 296.0) 0.957 (-527.6 to 328.3) | 0.174 (-472.4 to 56.42) 0.764 (-370.1 to 158.7) | >0.999 (-511.9 to 469.5) 0.877 (-318.2 to 617.6) | 0.958 (-124.2 to 197.2) <0.001 (194.2 to 421.5) | 0.859 (-201.5 to 405.2) 0.214 (-76.49 to 530.2) | 0.947 (-183.2 to 285.9) 0.220 (-70.20 to 398.9) | 0.975 (-889.8 to 643.8) 0.999 (-734.1 to 799.5) |
| 7. | CABS | 259.50±71.92 | 346.00±44.80 | 255.00±45.00 | 431.20±63.41 | 316.5±54.96* | 309.3±77.11* | 214.30±9.06 | 421.70±40.34* |
| | 100 | 0.500 (-182.9 to 631.5) 0.999 (-369.5 to 275.6) | 0.764 (-437.9 to 187.3) 0.916 (-401.9 to 223.3) | 0.192 (-119.0 to 812.0) 0.999 (-368.6 to 391.6) | 0.965 (-312.0 to 489.4) 0.097 (-3.20 to 758.2) | 0.911 (-311.7 to 171.3) 0.039 (9.819 to 492.8) | 0.916 (-356.2 to 222.5) 0.027 (29.82 to 608.5) | 0.996 (-196.0 to 158.7) 0.051 (-0.3646 to 354.4) | 0.999 (-422.6 to 385.9) 0.044 (-819.6 to -11.07) |
| 8. | CABS | 437.20±85.37 | 114.20±30.55 | 602.00±79.92* | 468.20±70.08 | 339.20±58.51 | 425.20±90.86 | 329.00±52.00 | 285.70±127.70 |
| | 500 | 0.997 (-360.5 to 453.9) 0.848 (-547.2 to 267.2) | 0.853 (-206.1 to 419.1) 0.670 (-170.1 to 455.1) | >0.999 (-380.6 to 379.6) 0.012 (-604.3 to -66.72) | 0.995 (-349.0 to 452.4) 0.163 (-80.20 to 721.2) | 0.770 (-334.3 to 148.7) 0.070 (-12.85 to 470.2) | 0.318 (-472.0 to 106.7) 0.233 (-86.01 to 492.7) | 0.343 (-283.7 to 71.03) 0.498 (-88.03 to 266.7) | 0.868 (-286.6 to 521.9) 0.230 (-683.6 to 124.9) |
| 9. | CABS | 323.30±110.7 | 349.80±42.79 | 555.00±75.00 | 358.30±107.5* | 253.0±81.77* | | 204.00±36.14* | 240.30±70.57 |
| | 1000 | 0.775 (-246.7 to 567.7) 0.999 (-433.4 to 381.0) | 0.775 (-246.7 to 567.7) 0.999 (-433.4 to 381.0) | 0.998 (-419.0 to 512.0) 0.179 (-668.6 to 91.61) | 0.760 (-239.2 to 562.2) 0.031 (29.64 to 831.0) | >1000 (-248.2 to 234.8) 0.031 (29.64 to 831.0) | | 0.996 (-158.7 to 196.0) 0.017 (36.97 to 391.7) | 0.682 (-241.3 to 567.3) 0.374 (-638.3 to 170.3) |
| 10. | CALD | 154.30±40.14 | 276.30±83.97 | 257.80±78.07 | 833.50±98.00 | 196.20±37.60 | 424.30±53.64 | 262.30±29.41* | 698.00±343.10 |
| | 100 | 0.068 (-12.94 to 540.1) 0.553 (-133.6 to 419.4) | 0.996 (-474.9 to 370.9) >0.999 (-442.5 to 403.2) | 0.957 (-492.9 to 305.6) >0.999 (-390.6 to 407.9) | 0.720 (-722.2 to 290.8) 0.999 (-527.7 to 438.1) | 0.979 (-431.7 to 632.3) 0.062 (-13.38 to 756.6) | 0.961 (-271.5 to 430.0) 0.441 (-146.5 to 555.0) | 0.882 (-110.2 to 196.2) 0.046 (2.777 to 309.2) | 0.965 (-1122 to 758.5) >0.999 (-966.8 to 914.2) |
| 11. | CALD | 144.20±41.06* | 108.00±52.25 | 630.7±151.10* | 555.20±119.70 | 734.50±35.37 | 523.80±81.90 | 254.30±29.08* | 554.00±35.10 |
| | 500 | 0.0253 (26.34 to 521.0) 0.380 (-94.33 to 400.3) | 0.787 (-40.39 to 19.73) 0.883 (-324.1 to 621.5) | 0.016 (-865.7 to -67.27) 0.086 (-763.4 to 35.06) | 0.996 (-443.8 to 569.1) 0.619 (-249.4 to 716.4) | 0.1246 (-957.2 to 81.15) 0.660 (-533.8 to 200.4) | 0.999 (-334.1 to 293.4) 0.859 (-209.1 to 418.4) | 0.805 (-102.2 to 204.2) 0.035 (10.78 to 317.2) | >0.999 (-978.5 to 902.5) 0.993 (-822.8 to 105.8) |
| 12. | CALD | 42.00±22.20** | 174.00±79.93 | 315.80±101.40 | 287.50±60.81* | 653.30±161.80 | 403.00±74.88 | 257.30±31.78* | 326.30±85.05 |
| | 1000 | 0.002 (134.8 to 653.6) 0.035 (14.17 to 533.0) | 0.997 (-372.5 to 473.2) 0.977 (-340.2 to 505.5) | 0.797 (-550.9 to 247.6) 0.996 (-448.6 to 349.9) | 0.334 (-176.2 to 836.8) 0.039 (18.26 to 984.1) | 0.277 (-876.0 to 162.3) 0.955 (-452.6 to 281.6) | 0.876 (-213.3 to 414.3) 0.244 (-88.25 to 539.3) | 0.837 (-105.2 to 201.2) 0.039 (7.777 to 314.2) | 0.960 (-750.8 to 1130) 0.747 (-595.2 to 1286) |
| 13. | CALS | 388.00±105.40 | 205.50±52.85 | 500.00±117.50 | 613.20±45.02 | 372.00±82.56 | 388.30±60.37 | 240.00±21.39* | 555.00±57.18** |
| | 100 | 0.958 (-315.6 to 507.2) 0.965 (-502.2 to 320.6) | >0.999 (-302.2 to 332.5) 0.989 (-266.2 to 368.5) | 0.971 (-403.1 to 606.1) 0.311 (-590.3 to 123.3) | 0.945 (-463.5 to 276.9) 0.638 (-194.7 to 545.7) | 0.579 (-373.5 to 122.2) 0.172 (-52.00 to 443.7) | 0.489 (-407.6 to 115.9) 0.083 (-21.61 to 501.9) | 0.994 (-162.0 to 127.3) 0.015 (33.68 to 323.0) | 0.736 (-557.8 to 254.4) 0.009 (-954.8 to -142.6) |
| 14. | CALS | 291.50±104.50 | 233.20±33.76 | 225.00±135.00 | 330.50±44.37* | 413.20±43.81 | 322.30±43.80* | 300.00±10.54 | 297.70±92.99 |
| | 500 | 0.650 (-219.1 to 603.7) >0.999 (-405.7 to 417.1) | >0.999 (-329.8 to 304.8) 0.999 (-293.8 to 340.8) | 0.378 (-241.6 to 994.6) 0.999 (-463.1 to 546.1) | 0.571 (-180.9 to 559.5) 0.010 (87.96 to 828.4) | 0.3057 (-414.7 to 81.00) 0.378 (-93.17 to 402.5) | 0.896 (-341.6 to 181.9) 0.016 (44.39 to 567.9) | 0.444 (-222.0 to 67.32) 0.125 (-26.32 to 263.0) | 0.849 (-282.4 to 529.8) 0.249 (-679.4 to 132.8) |
| 15. | CALS | 193.00±60.81 | 114.00±41.31 | 588.50±76.03 | 572.70±98.34 | 310.80±72.74* | 336.70±84.41* | 228.00±33.06* | 503.30±106.50* |
| | 1000 | 0.261 (-120.6 to 702.2) 0.944 (-307.2 to 515.6) | 0.859 (-210.7 to 424.0) 0.682 (-174.7 to 460.0) | >0.999 (-491.6 to 517.6) 0.088 (-678.8 to 34.83) | 0.993 (-423.0 to 317.4) 0.444 (-154.2 to 586.2) | 0.938 (-312.3 to 183.3) 0.039 (9.166 to 504.8) | 0.827 (-355.9 to 167.6) 0.024 (30.06 to 553.6) | >0.999 (-150.0 to 139.3) 0.010 (45.68 to 335.0) | 0.922 (-506.1 to 306.1) 0.016 (-903.1 to -90.90) |

Attraction towards the female (in seconds) for animals given extracts of *Citropsis articulata* rootbark decoction extracts at doses of 100 mg/kg (CABD 100), 500 mg/kg (CABD 500) and 1000 mg/kg (CABD 1000); *Citropsis articulata* rootbark Soxhlet extracts at doses of 100 mg/kg (CABS 100), 500 mg/kg (CABS 500) and 1000 mg/kg (CABS 1000); *Citropsis articulata* leaf decoction extracts at doses of 100 mg/kg (CALD 100), 500 mg/kg (CALD 500) and 1000 mg/kg (CALD 1000); and *Citropsis articulata* leaf Soxhlet extracts at doses of 100 mg/kg (CALS 100), 500 mg/kg (CALS 500) and 1000 mg/kg (CALS 1000). Values were The values are expressed as the means ± SEMs and then p-value (95% confidence interval) against the negative control, followed by comparisons against the positive control (below). N = 6 for days 0 to 28, whereas N = 3 for days 35 and 42 (no extracts were subsequently administered). Significant values (p-value ≤ 0.05) are marked in bold and with asterisks, where (*) indicates p ≤ 0.05, (**) indicates p ≤ 0.01, and (***) indicates p ≤ 0.001.

Table 3 Penile erections elicited by extracts

| No | Group | Day 0 | Day 3 | Day 7 | Day 14 | Day 21 | Day 28 | Day 35 | Day 42 |
|-----|-------|---|--|---|--|--|---|--|--|
| 1. | NC-DW | 0.33±0.33 | 0.83±0.40 | 0.00±0.00 | 2.40±0.87 | 1.50±0.50 | 1.67±0.61 | 0.67±0.67 | 5.33±1.45 |
| 2. | NC-DS | 0.00±0.00 | 0.00±0.00 | 0.00±0.00 | 0.83±0.54 | 0.17±0.17 | 0.00±0.00 | 0.67±0.67 | 0.33±0.33 |
| 3. | PC-SC | 0.67 ± 0.33 | 0.00±0.00 | 0.00±0.00 | 0.67±0.33 | 1.33±0.49 | 2.33±0.42 | 0.00±0.00 | 6.33±2.60 |
| 4. | CABD | 3.33±0.99* | 0.25±0.25 | 0.00±0.00 | 0.67±0.49 | 1.33±0.21 | 1.33±0.58 | 0.00±0.00 | 1.50±1.50 |
| | 100 | 0.035 (-5.841 to -0.159) 0.073 (-5.507 to 0.1740) | 0.748 (-0.8466 to 2.013) 0.985 (-1.680 to 1.180) | Std error =0 Std error =0 | 0.203 (-0.556 to 4.023) >0.999 (-2.183 to 2.183) | 0.999 (-1.825 to 2.158) >0.999 (-1.408 to 1.408) | 0.987(-1.634 to 2.301) 0.577 (-0.9677 to 2.968) | 0.525 (-0.8429 to 2.176) >0.999 (-1.510 to 1.510) | 0.618 (-5.609 to 13.28) 0.427 (-4.609 to 14.28) |
| 5. | CABD | 0.83±0.48 | 0.67±0.33 | 0.00±0.00 | 0.17±0.17 | 1.00±0.41 | 1.17±0.48 | 0.00±0.00 | 0.00±0.00 |
| | 500 | 0.985 (-3.341 to 2.341) 0.999 (-3.007 to 2.674) | 0.995 (-1.112 to 1.446) 0.548 (-1.946 to 0.6123) | Std error =0 Std error =0 | 0.058 (-0.056 to 4.523) 0.960 (-1.683 to 2.683) | 0.951 (-1.612 to 2.612) 0.967 (-1.241 to 1.908) | 0.943 (-1.468 to 2.468) 0.428 (-0.8010 to 3.134) | 0.525 (-0.8429 to 2.176) >0.999 (-1.510 to 1.510) | 0.541 (-6.610 to 17.28) 0.397 (-5.610 to 18.28) |
| 6. | CABD | 2.33±0.95 | 1.00±0.37 | 0.00±0.00 | 1.17±0.65 | 0.67±0.21 | 0.83±0.17 | 0.00±0.00 | 0.67±0.33 |
| | 1000 | 0.265 (-4.841 to 0.8407) 0.439 (-4.507 to 1.174) | 0.995 (-1.446 to 1.112) 0.177 (-2.279 to 0.2790) | Std error =0 Std error =0 | 0.519 (-1.056 to 3.523) 0.96 (-2.683 to 1.683) | 0.719 (-1.158 to 2.825) 0.621 (-0.7416 to 2.075) | 0.727 (-1.134 to 2.801) 0.199 (-0.4677 to 3.468) | 0.525 (-0.8429 to 2.176) >0.999 (-1.510 to 1.510) | 0.363 (-3.779 to 13.11) 0.220 (-2.779 to 14.11) |
| 7. | CABS | 0.33±0.33 | 0.00±0.00 | 0.00±0.00 | 0.50±0.34 | 0.17±0.17* | 0.00±0.00*** | 0.33±0.33 | 0.00±0.00* |
| | 100 | 0.960(-1.785 to 1.119) 0.960 (-1.119 to 1.785) | Std error =0 Std error =0 | >0.999 (-1.070 to 1.070) >0.999 (-0.873 to 0.873) | 0.963(1.151 to 1.818) 0.997 (-1.318 to 1.651) | >0.999 (-1.063 to 1.063) 0.026 (0.103 to 2.230) | >0.999 (-0.835 to 0.835) <0.001 (1.499 to 3.168) | 0.972 (-1.502 to 2.169) 0.972 (-2.169 to 1.502) | 0.999 (-5.130 to 5.796) 0.022 (0.8702 to 11.80) |
| 8. | CABS | 1.17±0.60 | 0.00±0.00 | 0.50±0.22 | 0.00±0.00 | 0.17±0.17* | 0.00±0.00*** | 0.67±0.33 | 0.00±0.00* |
| | 500 | 0.160 (-2.619 to 0.2854) 0.848 (-1.952 to 0.952) | Std error =0 Std error =0 | 0.412 (-1.373 to 0.3733) 0.139 (-1.118 to 0.1175) | 0.482 (-0.6513 to 2.318) 0.683 (-0.8180 to 2.151) | >0.999 (-1.063 to 1.063) 0.027 (0.1032 to 2.230) | >0.999 (-0.835 to 0.835) <0.001 (1.499 to 3.168) | >0.999 (-1.836 to 1.836) 0.754 (-2.502 to 1.169) | 0.999(-5.130 to 5.796) 0.022 (0.8702 to 11.80) |
| 9. | CABS | 0.17±0.17 | 0.00±0.00 | 1.00±0.00* | 0.50±0.34 | 0.00±0.00** | | 0.33±0.33 | 0.00±0.00 |
| | 1000 | 0.848 (-0.952 to 1.952) 0.997 (-1.619 to 1.285) | Std error =0 Std error =0 | 0.848 (-0.9520 to 1.952) 0.022 (-1.873 to -0.127) | 0.848 (-0.9520 to 1.952) 0.997 (-1.318 to 1.651) | 0.990 (-0.8968 to 1.230) 0.009 (0.2699 to 2.397) | | 0.972 (-1.502 to 2.169) 0.972 (-2.169 to 1.502) | 0.999 (-5.130 to 5.796) 0.972 (-2.169 to 1.502) |
| 10. | CALD | 0.50±0.50 | 0.83±0.31 | 0.17±0.17 | 2.00±0.93 | 0.60±0.24 | 0.25±0.25 | 0.00±0.00 | 2.00±1.16 |
| | 100 | 0.994(-1.404 to 1.070) 0.994 (-1.070 to 1.404) | >0.999 (-1.328 to 1.328) 0.368 (-2.161 to 0.4942) | 0.956 (-0.8726 to 0.539) 0.956 (-0.8726 to 0.539) | 0.993 (-2.358 to 3.158) 0.576 (-3.963 to 1.296) | 0.876 (-1.947 to 3.747) 0.822 (-1.327 to 2.794) | 0.306 (-0.6980 to 3.531) 0.055 (0.0314 to 4.198) | 0.920 (-2.020 to 3.354) >0.999 (-2.687 to 2.687) | 0.526 (-3.500 to 10.17) 0.296 (-2.500 to 11.17) |
| 11. | CALD | 0.00±0.00 | 1.25±0.48 | 0.00±0.00 | 2.83±0.65 | 4.83±0.54*** | 0.50±0.50 | 1.33±0.67 | 1.33±0.33 |
| | 500 | 0.898 (-0.7731 to 1.440) 0.408 (-0.4398 to 1.773) | 0.9186 (-1.901 to 1.068) 0.128 (-2.734 to 0.2342) | >0.999 (-0.706 to 0.706) >0.999 (-0.706 to 0.706) | 0.990 (-3.191 to 2.325) 0.142 (-4.796 to 0.4630) | 0.014 (-6.112 to -0.555) 0.0003 (-5.47 to -1.535) | 0.385 (-0.725 to 3.058) 0.061 (-0.0581 to 3.725) | 0.920 (-3.354 to 2.020) 0.511 (-4.020 to 1.354) | 0.364 (-2.833 to 10.83) 0.190 (-1.833 to 11.83) |
| 12. | CALD | 0.00±0.00 | 0.50±0.34 | 0.50±0.34 | 0.00±0.00 | 5.00±0.52* | 0.67±0.33 | 1.67±0.88 | 0.67±0.67 |
| | 1000 | 0.898 (-0.7731 to 1.440) 0.408 (-0.4398 to 1.773) | 0.944 (-0.9942 to 1.661) 0.798 (-1.828 to 0.8276) | 0.260 (-1.206 to 0.206) 0.260 (-1.206 to 0.2059) | 0.110 (-0.3580 to 5.158) 0.943 (-1.963 to 3.296) | 0.009 (-6.279 to -0.721) 0.0002 (-5.63 to -1.702) | 0.535 (-0.8914 to 2.891) 0.103 (-0.2248 to 3.558) | 0.739 (-3.687 to 1.687) 0.315 (-4.354 to 1.020) | 0.2384 (-2.167 to 11.50) 0.119 (-1.167 to 12.50) |
| 13. | CALS | 1.00±0.68 | 0.00±0.00 | 0.00±0.00 | 0.17±0.17 | 0.17±0.17* | 0.17±0.17*** | 0.33±0.33 | 0.33±0.33* |
| | 100 | 0.4134 (-2.661 to 0.661) 0.976 (-1.995 to 1.328) | Std error =0 Std error =0 | >0.999 (-1.100 to 1.100) >0.999 (-0.778 to 0.778) | 0.567 (-0.6321 to 1.965) 0.789 (-0.7987 to 1.799) | >0.999 (-1.063 to 1.063) 0.027 (0.1032 to 2.230) | 0.987 (-1.146 to 0.8123) <0.001 (1.188 to 3.146) | 0.964 (-1.366 to 2.033) 0.964 (-2.033 to 1.366) | >0.999 (-5.594 to 5.594) 0.035 (0.4062 to 11.59) |
| 14. | CALS | 0.67±0.33 | 0.00±0.00 | 0.00±0.00 | 0.17±0.17 | 0.00±0.00** | 0.17±0.17*** | 0.00±0.00 | 0.33±0.33* |
| | 500 | 0.763 (-2.328 to 0.9947) >0.999 (-1.661 to 1.661) | Std error =0 Std error =0 | >0.999 (-1.347 to 1.347) >0.999 (-1.100 to 1.100) | 0.567 (-0.6321 to 1.965) 0.789 (-0.7987 to 1.799) | 0.990 (-0.8968 to 1.230) 0.009 (0.2699 to 2.397) | 0.987 (-1.146 to 0.8123) <0.001 (1.188 to 3.146) | 0.702 (-1.033 to 2.366) >0.999 (-1.700 to 1.700) | >0.999 (-5.594 to 5.594) 0.035 (0.406 to 11.59) |
| 15. | CALS | 0.33±0.33 | 0.00±0.00 | 0.67±0.33 | 0.17±0.17 | 0.17±0.17* | 0.33±0.21*** | 0.67±0.33 | 0.33±0.33* |
| | 1000 | 0.976 (-1.995 to 1.328) 0.976 (-1.328 to 1.995) | Std error =0 Std error =0 | 0.382 (-1.767 to 0.433) 0.113 (-1.444 to 0.1112) | 0.567 (-0.6321 to 1.965) 0.789 (-0.7987 to 1.799) | >0.999 (-1.063 to 1.063) 0.027 (0.1032 to 2.230) | 0.853 (-1.312 to 0.6456) <0.001 (1.021 to 2.979) | >0.999 (-1.700 to 1.700) 0.702 (-2.366 to 1.033) | >0.999 (-5.594 to 5.594) 0.035 (0.4062 to 11.59) |

Penile erections (in number of time) for animals given extracts of *Citropsis articulata* rootbark decoction extracts at doses of 100 mg/kg (CABD 100), 500 mg/kg (CABD 500) and 1000 mg/kg (CABD 1000); *Citropsis articulata* rootbark Soxhlet extracts at doses of 100 mg/kg (CABS 100), 500 mg/kg (CABS 500) and 1000 mg/kg (CABS 1000); *Citropsis articulata* leaf decoction extracts at doses of 100 mg/kg (CALD 100), 500 mg/kg (CALD 500) and 1000 mg/kg (CALD 1000); and *Citropsis articulata* leaf Soxhlet extracts at doses of 100 mg/kg (CALS 100), 500 mg/kg (CALS 500) and 1000 mg/kg (CALS 1000). PC-SC: positive control–sildenafil citrate (5 mg/kg), NC-DW: negative control–distilled water (CABD and CALD), NC-DS: negative control–dimethyl sulfoxide (CABS and CALS). The values are expressed as the means ± SEMs and then as p values (95% confidence intervals) against the negative control, followed by comparisons against the positive control (below). N = 6 for days 0 to 28, whereas N = 3 for days 35 and 42 (no extracts were subsequently administered). Significant values (p-value ≤ 0.05) are marked in bold and with asterisks, where (*) indicates p ≤ 0.05, (**) indicates p ≤ 0.01, and (***) indicates p ≤ 0.001.

Table 4 Mount Latency

| No | Group | Day 0 | Day 3 | Day 7 | Day 14 | Day 21 | Day 28 | Day 35 | Day 42 |
|-----|-------|--------------------------|-------------------------|---------------------------------|--------------------------|--------------------------|--------------------------|--------------------------|--------------------------|
| 1. | NC-DW | 80.67±41.75 | 29.67±17.95 | 25.33±6.88 | 32.40±17.16 | 41.50±14.76 | 54.33±28.82 | 30.00±21.73 | 27.67±13.91 |
| 2. | NC-DS | 75.00±22.80 | 85.33±49.10 | 12.50±8.50 | 205.00±182.40 | 10.33±2.32 | 55.83±31.95 | 15.00±2.52 | 29.67±19.34 |
| 3. | PC-SC | 126.70 ± 82.79 | 93.00±87.71 | 21.00±10.28 | 7.83±2.59 | 2.83±0.60 | 67.17±37.48 | 9.33±6.36 | 138.30±109.90 |
| 4. | CABD | 22.33±12.66 | 7.50±4.63 | 64.00±30.82 | 47.67±20.70 | 52.50±25.58 | 50.00±34.92 | 126.70±60.06 | 450.50±406.50 |
| | 100 | 0.944 (-171.6 to 288.3) | 0.999 (-385.1 to 429.5) | 0.664 (-123.1 to 45.77) | 0.987 (-105.8 to 75.26) | 0.998 (-114.9 to 92.90) | >0.999 (-105.4 to 114.1) | 0.562 (-303.3 to 109.9) | 0.387 (-1210 to 364.4) |
| | | 0.674 (-125.6 to 334.3) | 0.970 (-321.8 to 492.8) | 0.572 (-127.4 to 41.44) | 0.658 (-126.1 to 46.48) | 0.631 (-153.6 to 54.23) | 0.990 (-92.58 to 126.9) | 0.390 (-323.9 to 89.26) | 0.636 (-1099 to 475.1) |
| 5. | CABD | 158.80±80.12 | 67.00±50.48 | 69.00±30.59 | 45.67±17.30 | 76.17±37.16 | 13.00±4.87 | 81.00±71.53 | 63.00±0.00 |
| | 500 | 0.854 (-308.1 to 151.8) | 0.998 (-401.6 to 327.0) | 0.513 (-124.2 to 36.84) | 0.992 (-103.8 to 77.26) | 0.862 (-138.6 to 69.23) | 0.802 (-68.41 to 151.1) | 0.921 (-257.6 to 155.6) | >0.999 (-1031 to 960.5) |
| | | 0.994 (-262.1 to 197.8) | 0.999 (-338.3 to 390.3) | 0.421 (-128.5 to 32.51) | 0.699 (-124.1 to 48.48) | 0.263 (-177.2 to 30.57) | 0.603 (-55.58 to 163.9) | 0.782 (-278.3 to 134.9) | 0.999 (-920.5 to 1071) |
| 6. | CABD | 26.83±12.22 | 268.30±156.10 | 16.67±8.37 | 49.33±33.60 | 70.00±29.59 | 9.17±3.54 | 64.00±24.79 | 44.67±20.58 |
| | 1000 | 0.957 (-176.1 to 283.8) | 0.327 (-603.0 to 125.6) | 0.998 (-71.84 to 89.18) | 0.981 (-107.5 to 73.59) | 0.926 (-132.4 to 75.40) | 0.747 (-64.58 to 154.9) | 0.981 (-240.6 to 172.6) | >0.999 (-721.1 to 687.1) |
| | | 0.708 (-130.1 to 329.8) | 0.620 (-539.6 to 189.0) | 0.999 (-76.18 to 84.84) | 0.623 (-127.8 to 44.81) | 0.344 (-171.1 to 36.73) | 0.540 (-51.75 to 167.7) | 0.901 (-261.3 to 151.9) | 0.987 (-610.5 to 797.8) |
| 7. | CABS | 69.67±30.41 | 31.33±11.93 | 5.50±0.50 | 49.17±29.31 | 150.80±83.86 | 262.70±150.4 | 251.30±219.40 | 92.33±60.99 |
| | 100 | >0.999 (-187.6 to 198.2) | 0.928 (-143.9 to 251.9) | 0.999 (-81.01 to 95.01) | 0.882 (-335.3 to 646.9) | 0.133 (-308.3 to 27.26) | 0.761 (-795.7 to 382.0) | 0.543 (-730.4 to 257.7) | 0.962 (-377.4 to 252.1) |
| | | 0.906 (-135.9 to 249.9) | 0.888 (-136.3 to 259.6) | 0.958 (-56.36 to 87.36) | 0.999 (532.4 to 449.8) | 0.102 (-315.8 to 19.76) | 0.790 (-784.4 to 393.4) | 0.522 (-736.0 to 252.0) | 0.987 (-268.7 to 360.7) |
| 8. | CABS | 63.83±44.17 | 35.00±16.04 | 10.17±2.75 | 191.50±183.50 | 16.17±4.13 | 304.30±252.0 | 74.00±52.09 | 8.00±5.69 |
| | 500 | 0.999 (-181.7 to 204.1) | 0.943 (-147.6 to 248.3) | >0.999 (-69.53 to 74.19) | >0.999 (-477.6 to 504.6) | >0.999 (-173.6 to 161.9) | 0.645 (-837.4 to 340.4) | 0.994 (-553.0 to 435.0) | 0.999 (-293.1 to 336.4) |
| | | 0.872 (-130.1 to 255.7) | 0.909 (-139.9 to 255.9) | 0.959 (-39.98 to 61.65) | 0.806 (-674.8 to 307.4) | 0.999 (-181.1 to 154.4) | 0.678 (-826.0 to 351.7) | 0.992 (-558.7 to 429.4) | 0.662 (-184.4 to 445.1) |
| 9. | CABS | 70.67±23.11 | 41.33±29.19 | 64.50±57.50 | 110.20±45.71 | 58.83±33.19 | | 103.30±73.85 | 137.30±81.60 |
| | 1000 | >0.999 (-188.6 to 197.2) | 0.965 (-153.9 to 241.9) | 0.383 (-140.0 to 36.01) | 0.979 (-396.3 to 585.9) | 0.912 (-216.3 to 119.3) | | 0.974 (-582.4 to 405.7) | 0.974 (-582.4 to 405.7) |
| | | 0.911(-136.9 to 248.9) | 0.911 (-136.9 to 248.9) | 0.361 (-115.4 to 28.36) | 0.972 (-593.4 to 388.8) | 0.862 (-223.8 to 111.8) | | 0.967 (-588.0 to 400.0) | >0.999 (-313.7 to 315.7) |
| 10. | CALD | 35.00±19.32 | 30.17±12.94 | 19.00±8.93 | 50.83±28.27 | 54.80±25.40 | 41.50±23.57 | 27.00±19.60 | 15.67±13.25 |
| | 100 | 0.970 (-169.8 to 261.1) | >0.999(-245.3 to 244.3) | 0.996 (-46.16 to 58.83) | 0.999 (-273.1 to 236.2) | 0.979 (-82.80 to 56.20) | 0.999 (-125.3 to 151.0) | >0.999 (-76.39 to 82.39) | >0.999 (-470.2 to 494.2) |
| | | 0.723 (-123.8 to 307.1) | 0.940(-182.0 to 307.7) | >0.999 (-50.49 to 54.49) | 0.984 (-285.8 to 199.8) | 0.213 (-121.5 to 17.54) | 0.980 (-112.5 to 163.8) | 0.944 (-97.06 to 61.73) | 0.913 (-359.6 to 604.9) |
| 11. | CALD | 34.00±6.78 | 250.80±133.70 | 28.50±13.85 | 129.80±84.32 | 16.83±3.64 | 108.00±105.00 | 26.00±22.07 | 71.33±20.63 |
| | 500 | 0.968 (-168.8 to 262.1) | 0.155 (-494.8 to 52.65) | 0.999 (-55.66 to 49.33) | 0.791 (-352.1 to 157.2) | 0.807 (-41.60 to 90.94) | 0.884 (-228.4 to 121.1) | 0.999 (-75.39 to 83.39) | 0.998 (-525.9 to 438.6) |
| | | 0.715 (-122.8 to 308.1) | 0.451 (-431.5 to 116.0) | 0.993 (-59.99 to 44.99) | 0.993 (-59.99 to 44.99) | 0.97 (-80.27 to 52.27) | 0.953 (-215.6 to 133.9) | 0.954 (-96.06 to 62.73) | 0.990 (-415.2 to 549.2) |
| 12. | CALD | 91.83±66.64 | 44.33±21.15 | 27.67±19.34 | 102.20±90.49 | 52.00±23.51 | 12.67±3.89 | 14.67±8.41 | 203.00±202.00 |
| | 1000 | 0.999 (-226.6 to 204.3) | 0.999 (-259.5 to 230.2) | >0.999(-54.83 to 50.16) | >0.999 (-54.83 to 50.16) | 0.990 (-76.77 to 55.77) | 0.846 (-81.89 to 165.2) | 0.966 (-64.06 to 94.73) | 0.754 (-657.6 to 306.9) |
| | | 0.989 (-180.6 to 250.3) | 0.976 (-196.2 to 293.5) | 0.996 (-59.16 to 45.83) | 0.782 (-337.1 to 148.4) | 0.219 (-115.4 to 17.10) | 0.679 (-69.06 to 178.1) | 0.999 (-84.73 to 74.06) | 0.991 (-546.9 to 417.6) |
| 13. | CALS | 65.17±10.18 | 67.50±25.88 | 39.33±13.77 | 68.83±28.58 | 11.00±3.89 | 145.20±76.58 | 1.00±1.00 | 52.00±10.69 |
| | 100 | >0.999 (-209.6 to 229.3) | 0.999 (-348.3 to 384.0) | 0.998 (-299.8 to 246.2) | 0.786 (-215.5 to 487.9) | >0.999 (-287.3 to 285.9) | 0.852 (-351.4 to 172.7) | 0.999 (-212.8 to 240.8) | >0.999 (-795.0 to 750.3) |
| | | 0.921 (-157.9 to 280.9) | 0.999 (-340.6 to 391.6) | 0.998 (-211.4 to 174.7) | 0.986 (-412.7 to 290.7) | >0.999 (-294.8 to 278.4) | 0.904 (-340.0 to 184.0) | >0.999 (-218.4 to 235.1) | 0.995 (-686.3 to 859.0) |
| 14. | CALS | 128.20±77.99 | 43.00±18.55 | 309.0±309.0* | 43.83±19.17 | 171.00±100.50 | 92.33±46.59 | 3.67±3.67 | 400.70±353.70 |
| | 500 | 0.952 (-272.6 to 166.3) | 0.997 (-323.8 to 408.5) | 0.096 (-630.8 to 37.84) | 0.666 (-190.5 to 512.9) | 0.483 (-447.3 to 125.9) | 0.994 (-298.5 to 225.5) | 0.999 (-215.4 to 238.1) | 0.540 (-1144 to 401.7) |
| | | >0.999 (-220.9 to 217.9) | 0.994 (-316.1 to 416.1) | 0.036 (-561.0 to -15.01) | 0.998 (-387.7 to 315.7) | 0.439 (-454.8 to 118.4) | 0.999 (-287.2 to 236.9) | >0.999 (-221.1 to 232.4) | 0.794 (-1035 to 510.3) |
| 15. | CALS | 55.50±19.89 | 335.30±166.50 | 40.00±13.33 | 58.83±37.21 | 168.80±117.00 | 119.50±97.16 | 145.00±108.70 | 12.67±11.20 |
| | 1000 | 0.999 (-199.9 to 238.9) | 0.293 (-616.1 to 116.1) | 0.998 (-300.5 to 245.5) | 0.740 (-205.5 to 497.9) | 0.497 (-445.1 to 128.1) | 0.951 (-325.7 to 198.4) | 0.382 (-356.8 to 96.77) | >0.999 (-755.7 to 789.7) |
| | | 0.873 (-148.3 to 290.6) | 0.322 (-608.5 to 123.8) | 0.998 (-212.0 to 174.0) | 0.993 (-402.7 to 300.7) | 0.451 (-452.6 to 120.6) | 0.976 (-314.4 to 209.7) | 0.345 (-362.4 to 91.10) | 0.981 (-647.0 to 898.3) |

Mount latency (in seconds) for animals given extracts of *Citropsis articulata* rootbark decoction extracts at doses of 100 mg/kg (CABD 100), 500 mg/kg (CABD 500) and 1000 mg/kg (CABD 1000); *Citropsis articulata* rootbark Soxhlet extracts at doses of 100 mg/kg (CABS 100), 500 mg/kg (CABS 500) and 1000 mg/kg (CABS 1000); *Citropsis articulata* leaf decoction extracts at doses of 100 mg/kg (CALD 100), 500 mg/kg (CALD 500) and 1000 mg/kg (CALD 1000); and *Citropsis articulata* leaf Soxhlet extracts at doses of 100 mg/kg (CALS 100), 500 mg/kg (CALS 500) and 1000 mg/kg (CALS 1000). PC-SC: positive control–sildenafil citrate (5 mg/kg), NC-DW: negative control–distilled water (CABD and CALD), NC-DS: negative control–dimethyl sulfoxide (CABS and CALS). The values are expressed as the means ± SEMs and then p-value (95% confidence intervals) against the negative control, followed by comparisons against the positive control (below). N = 6 for days 0 to 28, whereas N = 3 for days 35 and 42 (no extracts were subsequently administered). Significant values (p-value ≤ 0.05) are marked in bold and with asterisks, where (*) indicates p ≤ 0.05, (**) indicates p ≤ 0.01, and (***) indicates p ≤ 0.001.

Table 5 Mount frequency

| No | Group | Day 0 | Day 3 | Day 7 | Day 14 | Day 21 | Day 28 | Day 35 | Day 42 |
|-----|-------|---|---|--|---|--|---|--|--|
| 1. | NC-DW | 10.50±2.72 | 15.67±8.87 | 48.17±8.91 | 34.80±12.11 | 24.83±2.20 | 14.83±3.74 | 7.67±1.45 | 17.67±9.60 |
| 2. | NC-DS | 22.50±5.17 | 8.83±5.12 | 6.50±2.50 | 14.67±3.13 | 7.17±0.75 | 6.33±3.58 | 10.33±2.33 | 14.67±5.46 |
| 3. | PC-SC | 15.33±4.32 | 2.17±1.64 | 55.67±22.88 | 31.00±8.38 | 32.33±4.81 | 13.00±4.08 | 11.67±3.18 | 7.33±2.60 |
| 4. | CABD | 32.83±11.09 | 6.50±5.55 | 27.40±11.47 | 28.50±6.52 | 37.67±8.81 | 13.00±3.96 | 5.00±2.52 | 8.00±2.00 |
| | 100 | 0.277 (-54.47 to 9.806) 0.512 (-49.64 to 14.64) | 0.806 (-15.51 to 33.85) 0.985 (-29.01 to 20.35) | 0.833 (-37.85 to 79.39) 0.621 (-30.35 to 86.89) | 0.989 (-33.12 to 45.72) 0.999 (-35.08 to 40.08) | 0.500 (-36.13 to 10.46) 0.961 (-28.63 to 17.96) | 0.999 (-28.41 to 32.08) >0.999 (-30.24 to 30.24) | 0.313 (-249.6 to 58.31) 0.349 (-245.6 to 62.31) | 0.784 (-20.76 to 40.09) >0.99 (-31.09 to 29.76) |
| 5. | CABD | 9.17±4.25 | 1.50±0.62 | 20.17±7.71 | 30.67±7.47 | 35.83±4.14 | 16.00±7.72 | 10.00±1.53 | 63.00±0.00 |
| | 500 | >0.999 (-30.81 to 33.47) 0.979 (-25.97 to 38.31) | 0.347 (-7.908 to 36.24) >0.999 (-21.41 to 22.74) | 0.587 (-27.89 to 83.89) 0.359 (-20.39 to 91.39) | 0.998 (-35.28 to 43.55) >0.999 (-37.25 to 37.92) | 0.642 (-34.30 to 12.30) 0.992 (-26.80 to 19.80) | >0.999 (-31.41 to 29.08) 0.998 (-33.24 to 27.24) | >0.999 (-156.3 to 151.6) >0.999 (-152.3 to 155.6) | 0.616 (-22.82 to 54.15) 0.985 (-33.15 to 43.82) |
| 6. | CABD | 27.67±11.50 | 13.33±5.85 | 36.00±10.67 | 37.33±11.15 | 18.50±5.88 | 38.33±12.62 | 10.67±2.03 | 7.00±1.00 |
| | 1000 | 0.530 (-49.31 to 14.97) 0.791 (-44.47 to 19.81) | 0.998 (-19.74 to 24.41) 0.576 (-33.24 to 10.91) | 0.967 (-43.73 to 68.06) 0.836 (-36.23 to 75.56) | 0.999 (-41.95 to 36.88) 0.987 (-43.92 to 31.25) | 0.929 (-16.96 to 29.63) 0.427 (-9.465 to 37.13) | 0.184 (-53.74 to 6.745) 0.133 (-55.58 to 4.912) | >0.999 (-157.0 to 151.0) >0.999 (-153.0 to 155.0) | 0.645 (-16.55 to 37.88) >0.99 (-26.88 to 27.55) |
| 7. | CABS | 26.00±11.27 | 5.33±2.47 | 16.00±7.00 | 10.17±4.73 | 6.50±1.77* | 2.17±0.91 | 6.67±2.19 | 14.33±5.36 |
| | 100 | 0.997(-34.04 to 27.04) 0.841(-41.21 to 19.87) | 0.938 (-9.891 to 16.89) 0.956 (-16.56 to 10.22) | 0.999 (-121.8 to 102.8) 0.956 (-16.56 to 10.22) | 0.984 (-20.74 to 29.74) 0.142 (-4.407 to 46.07) | 0.984 (-20.74 to 29.74) 0.012(4.524 to 47.14) | 0.724 (-6.972 to 15.30) 0.058 (-0.3049 to 21.97) | 0.870 (-9.013 to 16.35) 0.699 (-7.680 to 17.68) | >0.99 (-20.64 to 21.31) 0.804 (-27.98 to 13.98) |
| 8. | CABS | 31.83±8.20 | 4.17±1.66 | 19.33±4.76 | 22.00±7.86 | 7.33±1.93* | 3.00±1.18 | 11.33±2.73 | 8.67±4.33 |
| | 500 | 0.895 (-39.87 to 21.21) 0.519 (-47.04 to 14.04) | 0.842 (-8.725 to 18.06) 0.992 (-15.39 to 11.39) | 0.991 (-104.6 to 78.90) 0.433 (-28.53 to 101.2) | 0.911 (-32.57 to 17.91) 0.831 (-16.24 to 34.24) | >0.999 (-21.48 to 21.14) 0.016 (3.691 to 46.31) | 0.836 (-7.805 to 14.47) 0.088 (-1.138 to 21.14) | 0.836 (-7.805 to 14.47) >0.999(-12.35 to 13.01) | 0.874 (-14.98 to 26.98) 0.999 (-22.31 to 19.64) |
| 9. | CABS | 21.00±5.55 | 9.50±3.77 | 33.00±5.00 | 16.33±4.52 | 19.67±10.06 | 5.00±3.06 | 6.67±4.18 | 6.67±4.18 |
| | 1000 | 0.999 (-29.04 to 32.04) 0.982 (-36.21 to 24.87) | 0.999 (-14.06 to 12.72) 0.506 (-20.72 to 6.058) | 0.999 (-14.06 to 12.72) 0.933 (-69.07 to 114.4) | 0.999 (-26.91 to 23.57) 0.448 (-10.57 to 39.91) | 0.439 (-33.81 to 8.809) 0.426 (-8.642 to 33.98) | 0.650 (-7.347 to 18.01) 0.459 (-6.013 to 19.35) | 0.722 (-12.98 to 28.98) >0.99 (-20.31 to 21.64) | |
| 10. | CALD | 28.67±3.67** | 12.33±4.59 | 37.00±13.15 | 41.00±5.83 | 26.00±6.35 | 25.75±8.27 | 19.33±7.69 | 17.67±9.08 |
| | 100 | 0.008 (-32.36 to -3.969) 0.073 (-27.53 to 0.8646) | 0.988 (-16.96 to 23.63) 0.584 (-30.46 to 10.13) | 0.972 (-42.39 to 64.72) 0.842 (-34.89 to 72.22) | 0.972 (-36.21 to 23.81) 0.839 (-38.62 to 18.62) | 0.999(-25.83 to 23.50) 0.941 (-18.33 to 31.00) | 0.822 (-41.74 to 19.91) 0.727 (-43.57 to 18.07) | 0.601 (-37.76 to 14.42) 0.864 (-33.76 to 18.42) | 0.99 (-30.06 to 30.06) 0.787 (-40.39 to 19.73) |
| 11. | CALD | 17.33±3.86 | 4.25±1.49 | 26.33±5.60 | 7.67±3.52 | 40.50±8.72 | 5.00±2.00 | 23.67±4.41 | 13.67±3.28 |
| | 500 | 0.625 (-21.03 to 7.365) 0.995 (-16.20 to 12.20) | 0.5804 (-11.27 to 34.10) 0.999 (-24.77 to 20.60) | 0.753 (-31.72 to 75.39) 0.506 (-24.22 to 82.89) | 0.09 (-2.879 to 57.15) 0.149 (-5.282 to 51.95) | 0.3135 (-39.18 to 7.848) 0.842 (-31.68 to 15.35) | 0.939 (-29.15 to 48.82) 0.971 (-30.99 to 46.99) | 0.324 (-42.09 to 10.09) 0.577 (-38.09 to 14.09) | 0.991 (-26.06 to 34.06) 0.953 (-36.39 to 23.73) |
| 12. | CALD | 4.67±2.01 | 5.50±2.25 | 13.17±4.92 | 6.83±3.46 | 23.67±4.70 | 37.17±10.07 | 42.00±8.15* | 6.33±4.10 |
| | 1000 | 0.748 (-8.365 to 20.03) 0.210 (-3.531 to 24.86) | 0.584 (-10.13 to 30.46) 0.988 (-23.63 to 16.96) | 0.334 (-18.56 to 88.56) 0.168 (-11.06 to 96.06) | 0.076 (-2.045 to 57.98) 0.127 (-4.449 to 52.78) | 0.999 (-22.35 to 24.68) 0.812 (-14.85 to 32.18) | 0.148 (-49.90 to 5.235) 0.103 (-51.74 to 3.402) | 0.010 (-60.42 to -8.243) 0.022 (-56.42 to -4.243) | 0.730 (-18.73 to 41.39) >0.99 (-29.06 to 31.06) |
| 13. | CALS | 27.00±5.94 | 10.67±4.39 | 7.33±2.01 | 20.67±4.15 | 6.33±1.59*** | 4.83±3.10 | 5.67±5.67 | 6.33±2.33 |
| | 100 | 0.976 (-27.15 to 18.15) 0.564 (-34.31 to 10.98) | 0.994 (-14.99 to 11.32) 0.345 (-21.66 to 4.657) | >0.999 (77.22 to 75.55) 0.092 (-5.679 to 102.3) | 0.906 (-26.32 to 14.32) 0.576 (-9.988 to 30.65) | 0.999 (-13.69 to 15.36) <0.001 (11.48 to 40.52) | 0.999 (-14.69 to 17.69) 0.584 (-8.027 to 24.36) | 0.990 (-29.46 to 38.79) 0.975 (-28.12 to 40.12) | 0.990 (-29.46 to 38.79) >0.99 (-43.89 to 45.89) |
| 14. | CALS | 16.17±6.53 | 1.17±0.48 | 6.00±6.00 | 10.17±2.65* | 14.67±5.90* | 4.17±2.68 | 1.00±1.00 | 4.67±0.88 |
| | 500 | 0.922 (-16.31 to 28.98) >0.999 (-23.48 to 21.81) | 0.445 (-5.490 to 20.82) 0.999 (-12.16 to 14.16) | >0.999 (-93.05 to 94.05) 0.317(-26.72 to 126.1) | 0.965 (-15.82 to 24.82) 0.043 (0.5120 to 41.15) | 0.562 (-22.02 to 7.024) 0.012 (3.142 to 32.19) | 0.995 (-14.03 to 18.36) 0.510 (-7.361 to 25.03) | 0.891 (-24.79 to 43.46) 0.837 (-23.46 to 44.79) | 0.944 (-34.89 to 54.89) 0.999 (-42.22 to 47.56) |
| 15. | CALS | 19.00±05.04 | 2.67±1.33 | 11.00±2.28 | 20.33±3.93 | 2.50±0.43*** | 12.67±5.48 | 18.33±14.84 | 23.00±20.55 |
| | 1000 | 0.991(-19.15 to 26.15) 0.989 (-26.31 to 18.98) | 0.648 (-6.990 to 19.32) >0.999 (-13.66 to 12.66) | 0.999 (-80.88 to 71.88) 0.133 (-9.346 to 98.68) | 0.922 (-25.99 to 14.65) 0.547 (-9.655 to 30.99) | 0.877 (-9.858 to 19.19) <0.001 (15.31 to 44.36) | 0.780 (-22.53 to 9.861) >0.999 (-15.86 to 16.53) | 0.933 (-42.12 to 26.12) 0.964 (-40.79 to 27.46) | 0.97 (-53.22 to 36.56) 0.779 (-60.56 to 29.22) |

Mount frequency (in number of time) for animals given extracts of *Citropsis articulata* rootbark decoction extracts at doses of 100 mg/kg (CABD 100), 500 mg/kg (CABD 500) and 1000 mg/kg (CABD 1000); *Citropsis articulata* rootbark Soxhlet extracts at doses of 100 mg/kg (CABS 100), 500 mg/kg (CABS 500) and 1000 mg/kg (CABS 1000); *Citropsis articulata* leaf decoction extracts at doses of 100 mg/kg (CALD 100), 500 mg/kg (CALD 500) and 1000 mg/kg (CALD 1000); and *Citropsis articulata* leaf Soxhlet extracts at doses of 100 mg/kg (CALS 100), 500 mg/kg (CALS 500) and 1000 mg/kg (CALS 1000). PC-SC: positive control–sildenafil citrate (5 mg/kg), NC-DW: negative control–distilled water (CABD and CALD), NC-DS: negative control–dimethyl sulfoxide (CABS and CALS). The values are expressed as the means ± SEMs and then p-value (95% confidence intervals) against the negative control, followed by comparisons against the positive control (below). N = 6 for days 0 to 28, whereas N = 3 for days 35 and 42 (no extracts were subsequently administered). Significant values (p-value ≤ 0.05) are marked in bold and with asterisks, where (*) indicates p ≤ 0.05, (**) indicates p ≤ 0.01, and (***) indicates p ≤ 0.001.

292 **Relative sexual organ weight and penile length of the animals**

293 Generally, the penile lengths increased (although slightly) with time as extract dosing
294 continued. However, with increasing extract dose, the penile length increased (Soxhlet
295 extracts) or decreased (decoctions). The highest penile length in the entire study was $13.17 \pm$
296 0.75 mm for the leaf decoction extract. Compared with the positive control (8.22 ± 0.48 mm),
297 the animals treated with the root bark Soxhlet extract at a dose of 1000 mg/kg had an average
298 penile length of 12.84 ± 0.35 mm, which was greater ($p = 0.021$: CI = -8.563 to -0.669).

299 The sexual organs (testes and penis) collected after 42 days of the study weighed more than
300 those collected after only 28 days of the study. With increasing dose, the weight of the sexual
301 organs decreased for the root bark extracts but generally increased for the leaf extracts (Table
302 6).

303 **Testosterone levels of the animals**

304 All the plant extracts at different doses resulted in more than twice the testosterone level of
305 the positive control, – sildenafil citrate after 28 days of administration. *Citropsis articulata*
306 leaf decoction extract at a dose of 500 mg/kg elicited a statistically significant increase in
307 testosterone, i.e., 14.50 ± 2.53 ng/ml ($p = 0.021$: CI = -19.45 to -1.553), as shown in Fig. 1.

308 After two additional weeks of extract administration, the testosterone levels of the extract
309 groups were less than half of those of the negative control, the distilled water group (Fig. 2).
310 These findings revealed a marked reduction in testosterone levels after sudden cessation of
311 extract treatment. *Citropsis articulata* root bark decoction extract at doses of 500 mg/kg and
312 1000 mg/kg resulted in significantly lower testosterone levels of 0.65 ± 0.13 and 0.96 ± 0.17
313 ($p = 0.040$: CI = 0.4607 - 21.00 and $p = 0.046$: CI = 0.1540 to 20.69), respectively.

314 **Histological analysis of sexual organs**

315 Following harvesting and microscopic analysis of the animals dosed with the test extracts for
316 28 days, the sexual organs generally appeared normal, with evidence of increased
317 spermatogenesis (dense concentration of spermatozoa), as noted in the epididymis and
318 seminiferous tubules of the testes (Fig. 3 – A and C). The penis also appeared normal with
319 prominent cavernous sinuses (Fig. 3 – B).





320 Nonetheless, following extract cessation for an additional 2 weeks, some of the harvested
321 sexual organs, such as the testes, seemed abnormal, with evidence of degenerate seminiferous
322 tubules and Leydig cells with extremely low levels of spermatozoa (Fig. 3 – D).

323 **Table 6** Relative sexual organ weight and penile length of the animals

| Organ | NC-DW | PC-SC | <i>Citropsis articulata</i> root bark decoction extract | | |
|---|--------------|--------------|---|--------------|----------------------------------|
| | | | 100 mg/kg | 500 mg/kg | 1000 mg/kg |
| <i>Harvested after 28 Days of Drug Administration</i> | | | | | |
| 1. Right testis | 1.49 ± 0.14 | 1.44 ± 0.04 | 1.45 ± 0.08 | 1.30 ± 0.03 | 1.34 ± 0.09 |
| 2. Left testis | 1.45 ± 0.18 | 1.49 ± 0.04 | 1.48 ± 0.12 | 1.40 ± 0.05 | 1.28 ± 0.24 |
| 3. Penile weight | 0.14 ± 0.01 | 0.16 ± 0.01 | 0.14 ± 0.01 | 0.13 ± 0.02 | 0.13 ± 0.02 |
| 4. Penile length | 8.15 ± 0.42 | 8.22 ± 0.48 | 8.51 ± 0.20 | 8.47 ± 0.29 | 8.09 ± 0.13 |
| <i>Harvested after Additional 14 Days of No Drug Administration</i> | | | | | |
| 5. Right testis | 1.48 ± 0.07 | 1.38 ± 0.06 | 1.54 ± 0.12 | 1.64 ± 0.06 | 1.63 ± 0.09 |
| 6. Left testis | 1.53 ± 0.09 | 1.59 ± 0.06 | 1.32 ± 0.26 | 1.69 ± 0.05 | 1.67 ± 0.19 |
| 7. Penile weight | 0.15 ± 0.00 | 0.19 ± 0.03 | 0.19 ± 0.01 | 0.16 ± 0.03 | 0.14 ± 0.02 |
| 8. Penile length | 10.74 ± 0.31 | 12.44 ± 2.13 | 12.01 ± 1.16 | 11.41 ± 0.47 | 10.59 ± 1.58 |
| Organ | NC-DS | PC-SC | <i>Citropsis articulata</i> root bark Soxhlet extract | | |
| | | | 100 mg/kg | 500 mg/kg | 1000 mg/kg |
| <i>Harvested after 28 Days of Drug Administration</i> | | | | | |
| 1. Right testis | 1.49 ± 0.08 | 1.44 ± 0.04 | 1.41 ± 0.09 | 1.46 ± 0.07 | 1.35 ± 0.01 |
| 2. Left testis | 1.62 ± 0.07 | 1.49 ± 0.04 | 1.59 ± 0.06 | 1.49 ± 0.06 | 1.39 ± 0.05 |
| 3. Penile weight | 0.17 ± 0.01 | 0.16 ± 0.01 | 0.18 ± 0.01 | 0.18 ± 0.02 | 0.21 ± 0.01 |
| 4. Penile length | 11.14 ± 0.97 | 8.22 ± 0.48 | 10.66 ± 1.00 | 11.71 ± 1.14 | 12.84 ± 0.35*^p |
| <i>Harvested after Additional 14 Days of No Drug Administration</i> | | | | | |
| 5. Right testis | 1.56 ± 0.09 | 1.38 ± 0.06 | 1.36 ± 0.06 | 1.30 ± 0.06 | 1.40 ± 0.03 |
| 6. Left testis | 1.55 ± 0.12 | 1.59 ± 0.06 | 1.25 ± 0.09 | 1.38 ± 0.08 | 1.49 ± 0.05 |
| 7. Penile weight | 0.19 ± 0.02 | 0.19 ± 0.03 | 0.20 ± 0.01 | 0.19 ± 0.01 | 0.19 ± 0.00 |
| 8. Penile length | 13.01 ± 1.09 | 12.44 ± 2.13 | 11.89 ± 0.43 | 12.16 ± 0.86 | 11.38 ± 0.85 |
| Organ | NC-DW | PC-SC | <i>Citropsis articulata</i> leaf decoction extract | | |
| | | | 100 mg/kg | 500 mg/kg | 1000 mg/kg |
| <i>Harvested after 28 Days of Drug Administration</i> | | | | | |
| 1. Right testis | 1.49 ± 0.14 | 1.44 ± 0.04 | 1.37 ± 0.09 | 1.41 ± 0.20 | 1.44 ± 0.02 |
| 2. Left testis | 1.45 ± 0.18 | 1.49 ± 0.04 | 1.61 ± 0.10 | 1.50 ± 0.13 | 1.48 ± 0.01 |
| 3. Penile weight | 0.14 ± 0.01 | 0.16 ± 0.01 | 0.15 ± 0.02 | 0.12 ± 0.01 | 0.11 ± 0.00 |
| 4. Penile length | 8.15 ± 0.42 | 8.22 ± 0.48 | 8.88 ± 0.90 | 8.84 ± 0.92 | 8.43 ± 0.33 |
| <i>Harvested after Additional 14 Days of No Drug Administration</i> | | | | | |
| 5. Right testis | 1.48 ± 0.07 | 1.38 ± 0.06 | 1.50 ± 0.01 | 1.43 ± 0.08 | 1.61 ± 0.11 |
| 6. Left testis | 1.53 ± 0.09 | 1.59 ± 0.06 | 1.51 ± 0.02 | 1.54 ± 0.04 | 1.65 ± 0.08 |
| 7. Penile weight | 0.15 ± 0.00 | 0.19 ± 0.03 | 0.19 ± 0.01 | 0.15 ± 0.01 | 0.17 ± 0.01 |
| 8. Penile length | 10.74 ± 0.31 | 12.44 ± 2.13 | 13.17 ± 0.75 | 10.33 ± 0.72 | 11.08 ± 0.96 |
| Organ | NC-DS | PC-SC | <i>Citropsis articulata</i> leaf Soxhlet extract | | |
| | | | 100 mg/kg | 500 mg/kg | 1000 mg/kg |
| <i>Harvested after 28 Days of Drug Administration</i> | | | | | |
| 1. Right testis | 1.49 ± 0.08 | 1.44 ± 0.04 | 1.51 ± 0.11 | 1.54 ± 0.08 | 1.51 ± 0.03 |
| 2. Left testis | 1.62 ± 0.07 | 1.49 ± 0.04 | 1.45 ± 0.06 | 1.64 ± 0.04 | 1.62 ± 0.06 |
| 3. Penile weight | 0.17 ± 0.01 | 0.16 ± 0.01 | 0.18 ± 0.02 | 0.16 ± 0.01 | 0.18 ± 0.02 |
| 4. Penile length | 11.14 ± 0.97 | 8.22 ± 0.48 | 10.69 ± 0.67 | 11.17 ± 0.82 | 11.03 ± 0.65 |
| <i>Harvested after Additional 14 Days of No Drug Administration</i> | | | | | |
| 5. Right testis | 1.56 ± 0.09 | 1.38 ± 0.06 | 1.31 ± 0.10 | 1.56 ± 0.12 | 1.49 ± 0.05 |
| 6. Left testis | 1.55 ± 0.12 | 1.59 ± 0.06 | 1.39 ± 0.08 | 1.67 ± 0.15 | 1.51 ± 0.05 |
| 7. Penile weight | 0.19 ± 0.02 | 0.19 ± 0.03 | 0.16 ± 0.00 | 0.17 ± 0.01 | 0.17 ± 0.00 |
| 8. Penile length | 13.01 ± 1.09 | 12.44 ± 2.13 | 11.18 ± 0.16 | 11.08 ± 0.86 | 11.79 ± 0.41 |

NC-DW – Negative control-distilled water, NC-DS – Negative control-dimethylsulfoxide, PC-SC – Positive control-sildenafil citrate. Penile length was measured in mm. The values are expressed as the means ± SEMs, and the p-value was compared with that of the positive control. Significant values (p-value ≤ 0.05) are marked in bold, and asterisks (*^p)


324
325
326




Key: PC-SC: positive control – sildenafil citrate at a dose of 5 mg/kg; NC-DW: negative control – distilled water; NC-DMSO: negative control, dimethylsulfoxide (containing 0.1% gum Arabic).

Fig. 1 Testosterone levels of animals given extracts for 28 days


The values are expressed as the means ± SEMs. Significant values (p-value ≤ 0.05) are marked in bold, and asterisks (*) with *^P refer to comparisons with the positive control.




Citropsis articulata root bark decoction



Citropsis articulata leaf decoction



Citropsis articulata root bark Soxhlet extract




Citropsis articulata leaf Soxhlet extract

Key: PC-SC: positive control – sildenafil citrate at a dose of 5 mg/kg; NC-DW: negative control – distilled water; NC-DMSO: negative control, dimethylsulfoxide (containing 0.1% gum Arabic).

Fig. 2 Testosterone levels of animals left for an extra 14 days without dosing

The values are expressed as the means ± SEMs. Significant values (p-value ≤ 0.05) are marked in bold, and asterisks (*) with *ⁿ refer to comparisons with the negative control.

344
345
346
347
348
349
350
351
352
353
354
355
356
357
358
359
360
361
362
363
364
365
366
367
368
369
370
371
372
373
374
375



Key: 1, 2 and 3 represent magnifications of 40×, 100× and 400×, respectively. **A** – epididymis tail (lsp – high dense/large numbers of spermatozoa), **B** – penis (cs – prominent cavernous sinuses, ur – urethra, bv – blood vessels), **C** – normal testis (st – numerous seminiferous tubules, lu – enlarged lumen reach in spermatozoa, sc – dense number of Sertoli cells, lsp – highly dense concentration of spermatozoa in lumen), **D** – degenerate testis (ds – degenerate seminiferous tubules, dlu – degenerate lumen of seminiferous tubules, dlc – degenerate Leydig cells)

Fig. 3 Histological analysis of sexual organs

376 **Discussion**

377 The validation of the traditional use of medicinal plants for sexual function is an area of
378 interest for research in the fields of ethnopharmacology and pharmacognosy. *Citropsis*
379 *articulata* is a prominent medicinal plant in Uganda and other parts of Africa that is used
380 traditionally for managing erectile dysfunction. In this study, we were able to validate the
381 presence of the following phytochemicals: alkaloids, saponins, L-arginine, flavonoids,
382 reducing sugars, coumarins, glycosides, and phytosterols, which were present in varying
383 amounts in the different extracts. Our findings are in agreement with those of Gakunga et al.
384 (2014), Oloro et al. (2016) and Vudriko et al. (2014).

385 Aphrodisiac parameters such as attraction towards the female (AF) in seconds, penile
386 erections (PEs), mount latency (ML) and mount frequency (MF) were studied for the
387 different extracts at 3 dose levels for 28 days with daily dosing and for an additional 14 days
388 without dosing to establish the sustained effects. High values of AF, PE and MF and low
389 values of ML indicate that the animals have considerable libido and sexual energy. This
390 finding highlights the role of psychic pathways in sexual function (20).

391 *Citropsis articulata* root bark and leaf decoction and Soxhlet extracts at different doses of
392 100, 50 and 1000 mg/kg presented varying AF values. This finding highlights the interest of
393 the male rats in the female rats as influenced by extract ingestion. All the extracts caused PEs
394 on different days during the study, including on days 35 and 42 (the last 14 days of no
395 dosing). *Citropsis articulata* root bark decoction elicited the highest value of PE. It is rich in
396 L-arginine, a known precursor of nitric oxide that promotes erections (21). This may explain
397 why the plant is sometimes referred to as a natural “Viagra.” The general decrease in ML
398 over time meant that the extracts reduced the time required to start sexual activity. The
399 decrease in ML still occurred even after cessation of extract dosing, i.e., on day 35. The

400 increasing MF with time could be attributed to the accumulation of androgens, especially
401 testosterone, whose production is influenced by saponins, flavonoids and other phytosterols
402 present in the extracts (10).

403 Although the relative sexual organ weights did not significantly differ, a slight increase was
404 noted compared with that of the positive and negative controls. The plant extracts increased
405 penile length, as observed for rats given *C. articulata* root bark Soxhlet extract at a dose of
406 1000 mg/kg. This may explain why some aphrodisiac medicinal plants are also used for
407 penile enlargement (4,22).

408 Upon further histological analysis of the sexual organs, a dense concentration of spermatozoa
409 was observed, which showed that the plant extracts enhanced spermatogenesis. This is in
410 agreement with Gakunga et al. (2014). Spermatogenesis is an important indicator of male
411 fertility and sexual function. Nonetheless, upon abrupt extract cessation and subsequent
412 analysis after 14 days, there was a low concentration of spermatozoa in the sexual organs.
413 This may indicate that prolonged extract administration and consequent abrupt cessation
414 could cause toxic reciprocal withdrawal effects on sexual organs. This is further noted by the
415 very low testosterone levels of the same group (23).

416 Although there were barely any statistically significant differences when the mean testosterone
417 levels of the extracts at different doses were compared with those of the negative and positive
418 controls, there was a noticeable increase in testosterone levels with increasing dose, except for
419 the *C. articulata* leaf decoction and *C. articulata* leaf Soxhlet extracts at a dose of 500 mg/kg.
420 In addition, the *C. articulata* leaf decoction at a dose of 500 mg/kg caused the highest
421 testosterone level. This generally showed that the extracts may increase testosterone levels due
422 to the presence of phytochemicals such as saponins, phytosterols, steroids, flavonoids and
423 amino acids such as L-arginine (10,24). The lowest testosterone levels were recorded for the

424 positive control (sildenafil citrate). This finding contradicts other reports that showed that
425 sildenafil citrate enhanced testosterone production (7,10,25). This could be due to differences
426 in the type and age of the animals used, their feeding habits, and their general housing
427 conditions (26).

428 During the 28-day dosing period, the rats presented increased testosterone levels compared
429 with those remaining for an additional 14 days without dosing. This finding revealed the
430 beneficial effects of the extracts during drug administration and their untoward effects after 14
431 days. This may be due to delayed effects and negative feedback mechanisms in the body,
432 similar to the effects of exogenous steroid withdrawal (23,27). This could also be related to
433 cases of degenerate testes when examined grossly and microscopically. This may explain why
434 traditionalists only recommend 3-day dosing for the use of *C. articulata* as an aphrodisiac (11).

435 **Conclusion**

436 The root bark and leaves of *C. articulata* likely possess aphrodisiac efficacy, owing to
437 positive alterations in male sexual behavior, testosterone analysis and histological
438 assessment. However, cessation of consumption after long-term intake can cause delayed
439 toxic effects on the testes, as shown histologically, and lower testosterone levels. Herbal
440 consumers should not use extracts of African cherry orange for long periods. Cessation of
441 consumption should be tapered down gradually.

442 This study also revealed that both the root bark and the leaf of *C. articulata* possess
443 comparable aphrodisiac efficacy. Herbal consumers may confidently use the plant's leaf
444 instead of the root bark, whose use predisposes the plant to endangerment and extinction.

445 **Abbreviations**

446 AF: Attraction towards the female; CABD: *Citropsis articulata* root bark decoction; CABS:
447 *Citropsis articulata* root bark Soxhlet; CALD: *Citropsis articulata* leaf decoction; CALS:

448 *Citropsis articulata* leaf Soxhlet; CI: Confidence interval; MF: Mount frequency; ML: Mount
449 latency; n: Number of observations; NC-DW: Negative control – distilled water; NC-DMSO:
450 Negative control – dimethylsulfoxide (containing 0.1% gum Arabic); p-value: Probability
451 value; PC-SC: positive control – sildenafil citrate at a dose of 5 mg/kg; PE: Penile erection;
452 SEM: Standard error of the mean

453 **Declarations**

454 **Ethics approval and consent to participate**

455 Ethical approval was sought from the Research Ethics Committee of Mbarara University of
456 Science and Technology under the reference number – MUREC 1/7. This was followed by
457 further approval from the Uganda Wildlife Authority (Reference number: COD/96/05) in
458 order to collect plant samples. Final approval (Reference number: HS683ES) was obtained
459 from the Uganda National Council for Science and Technology for government recognition
460 of the research study and approval from the Office of the President.

461 **Consent for publication**

462 Not applicable.

463 **Availability of data and materials**

464 The datasets used and/or analyzed during the current study are available from the
465 corresponding author on reasonable request.

466 **Competing interests**

467 The authors declare that they have no competing interests.

468 **Funding**

469 This study was funded by the Pharm-Biotechnology and Traditional Medicine Centre
470 (PHARMBIOTRAC), an Africa Center of Excellence II (ACE-II) Project hosted at Mbarara
471 University of Science and Technology. The funder was not involved in the conceptualization,
472 design, data collection, analysis, decision to publish, nor preparation of this manuscript.

473 **Authors' contributions**

474 ARA conceptualized and designed the study. He participated wholly in data collection and
475 wrote the original draft of the manuscript. TAA assisted in data collection and analysis. JT
476 assisted in supervision, mentorship and interpretation of the study findings. VSA also
477 participated fully in data collection and reviewing the draft manuscript. COA supported in
478 guiding experimental handling of the laboratory animals and data analysis. JRA reviewed the
479 draft manuscript and offered guidance in data collection. AAA supported in conceptualization
480 of the study methodology and later reviewed of the manuscript draft. AG reviewed and edited
481 the final manuscript draft while offering mentorship and research related resources. POE was
482 the overall supervisor, revised the manuscript and supported in funding acquisition. All
483 authors read and approved the final manuscript.

484 **Acknowledgements**

485 We appreciate the financial and material support of Mbarara University of Science and
486 Technology through the Pharm-Biotechnology and Traditional Medicine Centre, which
487 ensured the success of this research study. We also thank the laboratory officers including Dr.
488 Eneku Wilfred, Mr. Mugeni Victor, Mr. Kumureeba Lauben, Mr. Mutekanga Emmanuel, Mr.
489 Bright James, Ms. Tumwekwatse Lenus, Ms. Atuhaire Joan and Mr. Muganga Gershom who
490 worked tirelessly to ensure the success of this project.

491 **References**

- 492 1. Cayetano-Alcaraz AA, Tharakan T, Chen R, Sofikitis N, Minhas S. The management of
493 erectile dysfunction in men with diabetes mellitus unresponsive to phosphodiesterase
494 type 5 inhibitors. *Andrology*. 2023;11(2):257–69.
- 495 2. Singh R, Singh S, Jeyabalan G, Ali A. An overview on traditional medicinal plants as
496 aphrodisiac agent. *J Pharmacogn Phytochem*. 2012;1(4):43–56.
- 497 3. Svennersten K, Reus C. Etiology, surgical anatomy, and pathophysiology of male erectile
498 dysfunction. *International Journal of Reconstructive Urology*. 2024 Jun;2(1):4.
- 499 4. Kamatenesi-Mugisha M, Oryem-Origa H. Traditional herbal remedies used in the
500 management of sexual impotence and erectile dysfunction in western Uganda. *Afr Health*
501 *Sci*. 2005 Mar;5(1):40–9.
- 502 5. Namukobe J, Kasenene JM, Kiremire BT, Byamukama R, Kamatenesi-Mugisha M, Krief
503 S, et al. Traditional plants used for medicinal purposes by local communities around the
504 Northern sector of Kibale National Park, Uganda. *Journal of Ethnopharmacology*.
505 2011;136(1):236–45.
- 506 6. Tugume P, Kakudidi EK, Buyinza M, Namaalwa J, Kamatenesi M, Mucunguzi P, et al.
507 Ethnobotanical survey of medicinal plant species used by communities around Mabira
508 Central Forest Reserve, Uganda. *Journal of ethnobiology and ethnomedicine*.
509 2016;12(1):1–28.
- 510 7. Vudriko P, Baru MK, Kateregga J, Ndukui JG. Crude ethanolic leaf extracts of *Citropsis*
511 *articulata*: A potential phytomedicine for treatment of male erectile dysfunction
512 associated with testosterone deficiency. *Int J Basic Clin Pharmacol*. 2014;3(1):120–3.
- 513 8. Anywar G, Kakudidi E, Byamukama R, Mukonzo J, Schubert A, Oryem-Origa H.
514 Indigenous traditional knowledge of medicinal plants used by herbalists in treating

- 515 opportunistic infections among people living with HIV/AIDS in Uganda. *Journal of*
516 *Ethnopharmacology*. 2020 Jan 10;246:112205.
- 517 9. Amaza AR, Amutuhaire TA, Tusiimire J, Amito VS, Ajayi CO, Angupale JR, et al.
518 Pharmacognostical Evaluation and Description of the Leaf and Root Bark of *Citropsis*
519 *articulata* Swingle & Kellerman [Internet]. Rochester, NY; 2024 [cited 2024 May 21].
520 Available from: <https://papers.ssrn.com/abstract=4720183>
- 521 10. Gakunga NJ, Mugisha K, Owiny D, Waako P. Effects of Crude Aqueous Leaf Extracts of
522 *Citropsis Articulata* and *Mystroxylon Aethiopicum* on Sex Hormone Levels In Male
523 Albino Rats. *International Journal of Pharmaceutical Science Invention*. 2014
524 Jan;3(01):14.
- 525 11. Wangalwa R, Olet EA, Kagoro-Rugunda G, Tolo CU, Ogwang PE, Barasa B. Occurrence
526 of *Citropsis articulata* in Tropical Forests in Uganda: Implication for Ex Situ
527 Conservation. *International Journal of Forestry Research*. 2021 Mar 25;2021:e5582461.
- 528 12. Olupot W. Restoration of *Citropsis articulata*, a Species at Risk from Medicinal
529 Overharvesting in a Ugandan Rainforest Reserve. *International Journal of Forestry*
530 *Research*. 2021 Sep 21;2021:e7264632.
- 531 13. WHO. WHO guidelines on good agricultural and collection practices (GACP) for
532 medicinal plants. 2003.
- 533 14. Vishnu B, Sheerin FatimaMA, Sreenithi V. A Guide to Phytochemical Screening.
534 *IJARIIIE*. 2019 Jan 19;5(1):236–45.
- 535 15. Oloro J, Kihdze TJ, Katusiime B, Imanirampa L, Waako P, Bajunirwe F, et al.
536 Phytochemical and efficacy study on four herbs used in erectile dysfunction: *Mondia*
537 *whiteii*, *Cola acuminata*, *Urtica massaica*, and *Tarenna graveolens*. *AJPP*. 2016 Oct
538 8;10(37):785–90.

- 539 16. United States National Research Council. Guide for the Care and Use of Laboratory
540 Animals [Internet]. 8th ed. Washington (DC): National Academies Press (US); 2011
541 [cited 2024 Jun 12]. (The National Academies Collection: Reports funded by National
542 Institutes of Health). Available from: <http://www.ncbi.nlm.nih.gov/books/NBK54050/>
- 543 17. Sachs BD, Akasofu K, Citron JH, Daniels SB, Natoli JH. Noncontact stimulation from
544 estrous females evokes penile erection in rats. *Physiology & Behavior*. 1994;55(6):1073–
545 9.
- 546 18. Erhirhie EO, Ihekwereme CP, Ilodigwe EE. Advances in acute toxicity testing: strengths,
547 weaknesses and regulatory acceptance. *Interdisciplinary toxicology*. 2018;11(1):5–12.
- 548 19. Tian W, Wang L, Lei H, Sun Y, Xiao Z. Antibody production and application for
549 immunoassay development of environmental hormones: a review. *Chem Biol Technol*
550 *Agric*. 2018 Mar 5;5(1):5.
- 551 20. Singh R, Ali A, Govindasamy J, Semwal A, Jaikishan. An overview of the current
552 methodologies used for evaluation of aphrodisiac agents. *Journal of Acute Disease*. 2013
553 Dec 31;2:85–91.
- 554 21. Shafaei A, Aisha AFA, Siddiqui MJA, Ismail Z. Analysis of L-citrulline and L-arginine
555 in *Ficus deltoidea* leaf extracts by reverse phase high performance liquid
556 chromatography. *Pharmacognosy Res*. 2015;7(1):32–7.
- 557 22. Kyarimpa C, Nagawa CB, Omara T, Odongo S, Ssebugere P, Lugasi SO, et al. Medicinal
558 Plants Used in the Management of Sexual Dysfunction, Infertility and Improving Virility
559 in the East African Community: A Systematic Review. *Evidence-Based Complementary*
560 *and Alternative Medicine*. 2023 Aug 12;2023:e6878852.
- 561 23. Kesner AJ, Lovinger DM. Cannabis use, abuse, and withdrawal: Cannabinergic
562 mechanisms, clinical, and preclinical findings. *Journal of Neurochemistry*.
563 2021;157(5):1674–96.

- 564 24. Melis MR, Argiolas A. Erectile Function and Sexual Behavior: A Review of the Role of
565 Nitric Oxide in the Central Nervous System. *Biomolecules*. 2021 Dec 11;11(12):1866.
- 566 25. Spitzer M, Bhasin S, Travison TG, Davda MN, Stroh H, Basaria S. Sildenafil increases
567 serum testosterone levels by a direct action on the testes. *Andrology*. 2013 Nov;1(6):913–
568 8.
- 569 26. Chica-Rodríguez SDL, Cortés-Denia P, Ramírez-Expósito MJ, Saavedra JMA de,
570 Sánchez-Agesta R, Pérez MDC, et al. In vivo administration of doxazosin in rats highly
571 decreases serum circulating levels of testosterone through a mechanism involving the
572 testicular renin–angiotensin system. *International Journal of Andrology*. 2008;31(3):364–
573 70.
- 574 27. Margolin L, Cope DK, Bakst-Sisser R, Greenspan J. The Steroid Withdrawal Syndrome:
575 A Review of the Implications, Etiology, and Treatments. *Journal of Pain and Symptom*
576 *Management*. 2007 Feb 1;33(2):224–8.
- 577